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ABSTRACT 
Background 
Because resources are scarce in health care, costs and consequences of new interventions must 
be assessed to support informed policy decisions. This thesis analyses the cost-effectiveness of 
advanced postoperative pain treatment and perioperative haemodynamic optimization by 
applying decision modelling as an analytic framework. 
1. Postoperative pain treatment refers to epidural analgesia and to patient-controlled 
intravenous analgesia. Based on the superior analgesic effect found in clinical trials, epidural 
analgesia is regarded as the gold standard following major surgery, but a drawback is the high 
failure rate (10–15%). Considering that approximately 40 000 patients are treated by epidural 
analgesia per year in Sweden, costs and consequences of this clinical problem are substantial.  
2. Haemodynamic optimization refers to fluid protocols targeted to increase blood flow, 
referred to as goal-directed haemodynamic treatment. These protocols are beneficial in the 
perioperative care of high-risk patients, but there is lack of evidence in elderly patients. In 
Sweden 20 000 patients are operated on each year for proximal femoral fracture, with poor 
postoperative outcome. Large trials are required to assess whether any protocol of the goal-
directed haemodynamic treatment is beneficial in the elderly population, in terms of outcome 
and health care costs. Considering the cost and complexity of such a trial, a prior cost-
effectiveness analysis might be adequate to guide the initiation of such a trial. 
Methods  
1. Epidural analgesia vs. patient-controlled intravenous analgesia: 
Paper I: A decision-analytic cost-effectiveness model was developed to analyse data of a 
clinical database on pain treatment following major abdominal surgery. 
Paper II: Postoperative intensive care costs were analysed on data from patients included in a 
previously published trial on postoperative pain treatment following thoracoabdominal 
oesophagectomy. 
2. Goal-directed haemodynamic treatment vs. traditional fluid treatment in elderly patients: 
Paper III: A decision-analytic cost-effectiveness model was developed, and relevant data from 
published trials and national registries were analysed. As the clinical outcome for elderly 
patients was previously unknown, reasonable estimates are applied in the model. 
Paper IV: The prior cost-effectiveness analysis (Paper III) guided the initiation of a large 
(n = 460) randomized clinical trial in elderly patients with proximal femoral fracture, and 
interim analyses of safety and efficacy were conducted (n = 100). Given the interim efficacy 
data, the monetary value of further data collection was analysed by calculating the expected 
value of perfect information. 
Results 
1. The epidural analgesia is not cost-effective and no saving of the postoperative costs can be 
achieved, given the available evidence in Swedish clinical routine (Papers I–II). 
2. The goal-directed haemodynamic treatment is predicted to be cost-effective in elderly 
patients, based on the available evidence and on the prior estimates of clinical outcome before 
the initiation of the trial. The expected value of perfect information is high, indicating that 
collecting further data by continuing the trial is potentially worthwhile (Papers III–IV). 
Conclusions 
1. The analyses of epidural analgesia challenge its position as the gold standard and may assist 
revision of clinical policy decisions on postoperative pain treatment. 
2. The analyses of the goal-directed haemodynamic treatment in elderly patients using a 
decision-analytic cost-effectiveness model suggest the usefulness of the initiation and 
continuation of a large clinical trial.  
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1 INTRODUCTION 
At the clinical level decisions to adopt new interventions are usually assisted by evidence-
based efficacy, that is, how these interventions can ideally work. Often there is a lack of 
knowledge as to clinical effectiveness, that is, how these new interventions actually work in the 
clinical routine care and also whether it is reasonable to strain the clinical budget with 
additional costs. Clinicians are important actors in adoption decisions and in such positions two 
types of barriers may be experienced: i) the first prevents the adoption of new interventions 
with a high grade of evidence-based efficacy
1
 ii) the second prevents revision of previously 
adopted interventions when new evidence comes up. I initiated this thesis based on my clinical 
awareness of these barriers, which is grounded in the understanding of two separated issues: 
1. Beside evidence of efficacy, analyses of costs and consequences are also needed to influence 
the adoption procedure. 
2. For the revision of already adopted treatments a dynamic framework is required to update 
the evidence with new findings. 
Such assessments are the key features of health economic evaluations. This thesis is devoted to 
applying established analytic frameworks in health economics to assess two common 
interventions in perioperative medicine. 
 
1.1 BACKGROUND 
During the past decade the number of operations involving the cardiovascular, intrathoracic, 
and gastrointestinal organs has doubled from approximately 80 000 to 160 000 per year.
i
 
During the same period the inpatient health care costs have increased by 30 per cent, the 
number of patients over 65 years increased representing 13.5 per cent in 2007.
ii
 At the same 
time the number of hospital beds and the length of hospital stay have decreased. In 2007 the 
mean length of hospital stay was 6.1 days. These changes require adoption of new strategies in 
perioperative care to accelerate postoperative recovery by minimizing the physiological 
disturbances associated with surgical trauma and anaesthesia. New approaches to preoperative 
assessment using new biomarkers or exercise testing
2,3
, new approaches to fluid treatment 
using new monitoring technologies
4,5
, and advanced recovery and pain treatment programs 
have been proposed and partially implemented. However, resources in health care are scarce, 
and not all new opportunities can be introduced. Therefore, it is necessary to identify treatment 
strategies that offer the greatest patient benefits in relation to costs. Such assessments are the 
objectives of health economic evaluations. Health economic evaluations provide an analytic 
framework to compare alternative interventions in terms of costs and consequences. The 
alternative interventions are the range of options that could be used to increase the population‟s 
health. Costs refer to the value of health care resources used. Consequences represent clinical 
effects, including changes in patients‟ health. Health economic evaluations aim to assist the 
decision-making process on the use of new treatment strategies to maximize health in the 
population, given the limited resources in health care. Such analyses are a part of a 
prioritization process in health care according to Swedish law.
iii
 
The increased use of economic evaluation in health care decisions has induced a rationale of 
strict analytic frameworks; one of them is decision analytic modelling. 
This thesis applies decision analytic models to analyse the costs and consequences of two 
common interventions within anaesthesia care: postoperative pain treatment and perioperative 
haemodynamic optimization. Common features of both treatments are that they involve a large 
                                                 
i
 http://www.socialstyrelsen.se/statistik/statistikdatabas. 
ii
 http://www.socialstyrelsen.se/publikationer2009/2009-126-72. 
iii
 http://www.riksdagen.se/webbnav/index.aspx?nid=3911&bet=1982:763. 
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number of patients; they may influence the postoperative outcome, patient‟s postoperative 
health, and the length of hospital stay. 
1. Treatment of postoperative pain 
In Sweden approximately 40 000 patients per year undergo major abdominal surgery. The most 
commonly used pain treatment strategies are epidural infusion of a mixture of local anaesthetics 
and opiates with or without patient control (EDA/PCEA) and patient-controlled administration 
of intravenous opiates (PCIA). Consensus is found concerning the superior analgesic effect of 
EDA over PCIA,
6
, but not concerning the influence on postoperative complications
7-10
 or on the 
length of hospital stay.
11-19
 It is also unclear whether the better analgesic effect is clinically 
meaningful or can be translated into patient-oriented outcome.
20
 EDA
i
 is regarded as the gold 
standard for routine postoperative pain treatment following major abdominal surgery, based on 
the superior analgesia in efficacy trials. The low success rates (75–85%) in clinical practice21-24 
and the insufficient evidence of patient-oriented
20
 and clinical
10
 outcomes should challenge this 
position. 
2. Perioperative haemodynamic optimization 
The rationale of haemodynamic optimization is to increase the global blood flow in critical 
situations to prevent organ failure. It covers various treatment protocols that are referred to as 
goal-directed haemodynamic treatment (GDHT). The GDHT can be guided by a variety of 
haemodynamic parameters such as blood flow in the aorta,
25
 oxygen delivery,
26
 stroke 
volume,
27
 central venous pressure,
28
 central venous oxygen saturation,
29
 pulse pressure,
30
 and 
stroke volume variation.
31
 In high-risk patients the GDHT can influence the postoperative 
outcome,
4,5,32-39
 but there is scarce evidence in elderly patients with proximal femoral fracture. 
In this thesis the GDHT refers to an approach described by Shoemaker
40
 that is targeted by 
goal values of haemodynamic parameters (oxygen delivery >600 ml ∙ min-1 ∙ m-2, cardiac index 
>4.5 l ∙ min-1 ∙ m-2). The GDHT is unproven in clinical practice in elderly patients. Controlled 
clinical trials are required to also address health economic aspects; if results favour the GDHT, 
the adoption decision could have implications for approximately 20 000 treatments per year in 
Sweden. 
 
1.2 AIMS 
The specific aims in this thesis are: 
1. To analyse the costs and effects of postoperative epidural and patient-controlled 
intravenous analgesia following major abdominal surgery in routine clinical care (Paper I). 
2. To determine the influence of postoperative patient-controlled epidural and intravenous 
analgesia on the perceived nursing workload transformed into postoperative costs on the 
Intensive Care Unit following thoracoabdominal oesophagectomy (Paper II). 
3. To establish a prior estimation of cost-effectiveness of goal-directed haemodynamic 
treatment of elderly patients with proximal femoral fracture to guide the initiation of a 
randomized clinical trial (RCT) with the same objective (Paper III). 
4. To evaluate the monetary value of further data collection, given the interim efficacy data of 
the initiated RCT on GDHT of elderly patients with proximal femoral fracture by 
calculating the expected value of perfect information (Paper IV). 
                                                 
i In the thesis the term EDA is used as the abbreviation of epidural analgesia, irrespective of whether it is delivered 
by fixed rate pump or by patient-controlled pump, with one exception: EDA and PCEA are distinguished in the 
chapter in which Papers I–II are presented.  
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1.3 OUTLINE OF THE THESIS 
Chapter 3 provides a brief introduction to health economic evaluations, including analytic 
strategies. Chapter 4 presents the analytic framework used in the studies. Chapter 5 includes 
the studies on postoperative pain treatment, and Chapter 6 the studies on haemodynamic 
optimization. Chapter 7 contains the implications of modelling and the conclusions. The 
Appendix provides further relevant details on the modelling of GDHT, on the data collection 
(search of literature and registries), measures of outcomes (postoperative morbidity, mortality, 
health-related quality of life, long-term survival), and data incorporation that could not be 
included in the papers because of the limited space available in the journals. 
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2 HEALTH ECONOMIC EVALUATIONS - OVERVIEW 
As noted above, health economic evaluation compares costs and consequences of alternative 
treatment options. Such comparisons are required for policy decisions in a publicly funded 
health care system to ensure that the available health care resources are used to maximize the 
health of the population. 
 
2.1 BASIC FORMS OF ECONOMIC EVALUATION 
The basic forms of health economic evaluation are defined by the applied perspectives, the 
way consequences are valued, and the analytic strategy used. In all forms of health economic 
evaluations at least two alternatives are compared with each other, the intervention and the 
comparator (which is often standard treatment). 
 
2.1.1 The perspective 
Two perspectives are common in health economic evaluations. One is the societal perspective, 
which involves all relevant costs and consequences. Besides health care costs, changes in the 
patient‟s or family‟s productivity and the use of family resources affecting the work or leisure 
activities are also considered. The second is the health care perspective, which considers only 
health care costs and health outcomes strictly associated with the treatment. In the present 
thesis a health care perspective is taken.
41
  
 
2.1.2 Value of consequences 
There are four different types of economic evaluation, depending on which type of 
consequence is used.
41
  
1. Cost-effectiveness analysis: costs are related to a single common effect, for example, a gain 
in life-years, or pain-free or angina-free days. When the common effect is expressed by a 
generic measure of health (quality of life), it provides a possible comparison between 
interventions in health conditions with different clinical outcomes. 
2. Cost-utility analysis: the outcome is converted into a preference-based outcome measure. 
Normally quality-adjusted life-years (QALYs) are used, which combine the health-related 
quality of life of a health state with the duration of that health state. It can be considered as 
special case of cost-effectiveness analysis and the two terms are often used 
interchangeably. 
3. Cost-benefit analysis: the outcome is converted to monetary value; for example, reduced 
length of hospital stay is converted into hospital costs.  
4. Cost-minimization analysis: this type of economic evaluation searches for the least costly 
alternative when the size of the effects is similar. 
 
2.1.3 Analytic strategies 
The analytic strategies are defined by the methods of data collection and analysis. Data can be 
collected from a single clinical trial, or alternatively, drawn from different data sources using 
analytic models; these strategies can be combined.
41
 The key feature of data collection is to 
identify relevant, unbiased data with high precision.
42
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2.1.3.1 Clinical trials for health economic evaluation 
Randomized clinical trials generally provide the most unbiased evidence on outcomes, and 
have a high degree of internal validity, but they may have a low degree of external validity for 
some of the reasons given below. Use of the clinical trial as a single data source has several 
drawbacks.
41
  
1. Clinical trials are designed to find evidence of short-term efficacy rather than safety and 
effectiveness, and may lack precision with respect to clinical endpoints occurring rarely 
(side or adverse effects) that are relevant for policy decision on a population basis. 
2. The majority of trials that are designed to explore intermediate or surrogate outcomes do 
not assess relevant health outcomes and are too small to detect differences in mortality and 
morbidity. The intermediate or surrogate outcomes have to be „translated‟ into morbidity, 
mortality, and health outcome by epidemiologic data, if any exists. 
3. The follow-up of clinical trials is, as a rule, shorter than is required for health economic 
evaluations, as many health conditions and treatments require a lifelong perspective. 
4. The cost estimates of interest in a clinical trial may be biased, because part of the costs is 
protocol-driven rather than attributable to the therapy. 
5. The estimated sample size of efficacy trials is usually lower than is required for evidence of 
cost-effectiveness; that may lead to ethical financial considerations as to whether the trial 
should be continued, if evidence of efficacy is reached. 
 
2.1.3.2 Decision analytic modelling 
As noted above, the use of a single clinical trial for economic evaluation is not always possible 
because of the limited number of observations, short follow-up, and failure to collect relevant 
outcome data required for a health economic evaluation. Therefore, data have to be drawn from 
several data sources, if relevant policy issues are to be highlighted.
42
 An analytic framework, a 
model, provides a network between ranges of data sources, using mathematical relationships. 
The data incorporated in the model are called parameters. The parameters are estimated or 
defined, depending on which kinds of data are available. In the early assessment of a 
technology, sampled variables are not available and the parameters may be estimated by 
experts, based on empirical or theoretical knowledge.
41
 When sampled variables are available, 
the parameters may be defined by means of these. Such models are deterministic models, 
because point estimates are used (mean values or expert estimates). Another option is to define 
the parameters by probability distributions that characterize the uncertainty of the sampled 
variables; in this case the model is probabilistic.
42
 The probabilistic models address two 
separate key decisions. One is the decision to choose between alternative interventions based 
on costs and health outcomes, and the other is the decision as to whether further information is 
needed to decrease the uncertainty of this decision. This analysis is done by the estimation of 
the value of further research. 
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3 THE ANALYTIC FRAMEWORK 
In this thesis cost-effectiveness
i
 is analysed. The analytic strategy is modelling; deterministic 
model analysis was used in Papers I–III and probabilistic analysis in Paper IV (Table 1). Paper 
II represents a cost-minimization analysis where modelling and data collection alongside a 
clinical trial are combined. 
 
Table 1. Summary of the form of economic evaluation and the analytic strategies used in the papers  
Economic evaluation Paper I Paper II Paper III Paper IV 
Form Cost-
effectiveness 
Cost-
minimization 
Cost-
effectiveness 
Expected value 
of perfect 
information*  
Analytic strategy Deterministic 
model 
Deterministic 
model  
and clinical trial 
Deterministic 
model  
Probabilistic 
model 
* The expected value of perfect information is based on the cost-effectiveness analysis. 
 
This chapter presents the principles of cost-effectiveness analysis and the analytic methods 
used. 
1. Cost-effectiveness analysis (Papers I–III) 
2. Construction of decision analytic models (Papers I–IV) 
a.  Deterministic model (Papers I–III) 
b.  Probabilistic model (Paper IV) 
3.    Estimation of the value of further research by calculating the expected value of perfect 
information (Paper IV) 
 
3.1 COST-EFFECTIVENESS ANALYSIS 
As noted previously, cost-effectiveness analysis is one form of health economic evaluation.  
 
3.1.1 Costs 
Costs in this thesis refer to resources used in the health care. The cost analysis has the 
following steps. First, the relevant range of cost items is identified, then the use of resources is 
quantified (measured or estimated), and finally, the evaluation by monetary terms, that is, by 
assignment of prices.  
  
3.1.1.1 Cost items 
The cost items in this thesis include costs of personal care, technical equipment; medical 
devices, drugs, and hospital stay (postoperative care unit, intensive care unit, and general 
ward). 
 
3.1.1.2 Quantification of the resources used 
For the procedures of postoperative pain treatment (Papers I–II) and of haemodynamic 
optimization (Papers III and IV) the time devoted to the particular activities, and the number of 
medical devices and quantity of drugs used were measured in the clinical practice. The length 
                                                 
i
 In this thesis the term cost-effectiveness analysis is used also when quality-adjusted life-years are used as 
outcome measure. 
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of stay on the intensive care unit (Paper II) and on the general ward (Papers III and IV) was 
measured by individual data collection alongside clinical trials. In Paper II nursing workload 
on the intensive care unit (ICU) was measured by nursing scores alongside a clinical trial. 
 
3.1.1.3 How prices were assigned 
The price per hour per person was obtained from the hospital Accounting Department; the 
prices of technical equipment, medical devices, and drugs were obtained from the hospital 
pharmacy and Accounting Department. The price per hospital bed-days and per nursing score 
was established by the hospital Accounting Department. 
 
3.1.2 The measure of effect 
In cost-effectiveness analysis both clinical measures and measures of health can be used.
41
  
 
3.1.2.1 Number of pain-free days 
In the cost-effectiveness analysis of postoperative pain treatment (Paper I) the number of pain-
free days was used as the primary clinical outcome. The pain was measured as pain intensity 
on a visual analogue scale (VAS 1–100 mm), both at rest and during activity throughout a 
whole day. The measure of effect was 3 if the patient had 3 pain-free days, 2 in the case of 2 
pain-free days, 1 in the case of 1 pain-free day, and 0 if the patient did not experience VAS 30 
at all. 
 
3.1.2.2 Quality-adjusted life-years 
In the studies on haemodynamic optimization (Papers III and IV) quality-adjusted life-years 
are used as health outcome. The advantage of QALYs is that comparisons of cost-effectiveness 
can be made across disease areas. In the Appendix a detailed description of QALYs is given. 
The QALY combines the quality and quantity of life in a single measure. QALYs are 
calculated by quality adjustment weights (QALY weights), where 0 represents dead and 1.0 
represents full health, multiplied by the time spent in the actual health state. 
 
3.1.3 Incremental cost-effectiveness ratio 
The result of the cost-effectiveness analysis is expressed as the incremental cost-effectiveness 
ratio (Papers I and III). First the cost-effectiveness ratio (CER) is calculated, that is, the mean 
cost of reaching a particular outcome. 
CER=
Effect
Cost
 
When a decision has to be made whether to replace a treatment with a more expensive and 
more effective treatment, an estimate of the additional resources needed to obtain the 
additional effect is expressed as the incremental cost-effectiveness ratio (ICER):  
E
C
EffectEffect
CostCost
BA
BAICER
)(
)(
 
 
where C is the difference between costs and E is the difference between effects of two 
alternatives (A and B). The interpretation of the ICER is demonstrated in Fig. 1. 
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Fig. 1. Illustration of cost-effectiveness ratio (CER) and incremental cost-effectiveness ratio (ICER). 
The slopes of the dotted lines from origin represent the CERs of treatments A and B and the slope of the 
dotted line between A and B is the ICER. This is the estimate of the additional resources that would 
have to be used to obtain the additional effect. 
 
In Fig. 2 the cost-effectiveness plane is illustrated, where the incremental costs (vertical axis) 
are plotted against the incremental effects (horizontal axis) of four hypothetical treatments (A 
to D) when compared to relevant alternatives. Treatment B is dominant; it is less costly and 
better than the comparator (negative ∆C, positive ∆ E), and ICER calculation is not required. 
Treatment C is more costly and less effective (negative ∆C and ∆ E); it is not cost-effective. 
For treatments A and D the ICER calculation is needed, and it has to be related to the threshold 
value that society is willing to pay per one additional year with full health, denoted λ (the slope 
of the dotted line, also called the cost-effectiveness threshold). In Sweden there is no fixed 
value or official range of willingness to pay; Paper IV refers to a cost range of €20 000–50 000. 
The treatments below the dotted line are cost-effective, while those above and to the left of the 
line are cost-ineffective (Treatments C and D). 
 
Fig. 2. Illustration of the cost-effectiveness plane with the threshold value of what the society is willing 
to pay for one additional year with full health (λ, the slope of the dotted line). 
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3.2 CONSTRUCTION OF A MODEL 
The purpose of modelling is to illustrate the course of events following a decision between 
alternative options. Two types of models are used in this thesis, the decision tree and the 
Markov structure.
42
 The development of a model requires specification of the decision 
problem, definition of the model structure, of the time horizon, and the boundaries of the 
model, and identification of the available evidence. These steps are detailed in Papers I–III, and 
further details on Papers III–IV are given in the Appendix. Below a brief description and 
examples of the model structures are given. 
 
3.2.1 Decision tree 
A decision tree is constructed in all Papers (Fig. 3). It starts with the decision represented by a 
rectangle between the two alternatives followed by a circle (a chance node) where alternative 
events are possible; these are illustrated by branches coming out from chance node, 
representing the clinical pathways. At the ends of the branches are end nodes (triangles) 
representing outcomes. The pathways are mutually exclusive and are characterized by the 
probabilities; the sum of probabilities following each node is 1.0. Each pathway is associated 
with health care costs and an outcome. The expected costs and effects are based on the 
summation of pathway values weighted by the pathway probabilities. The calculation is 
illustrated in Fig. 3. 
 
Fig. 3. Example of a decision tree. The values in this decision tree are only to demonstrate how the 
costs and effects are calculated. 
 
3.2.2 Markov structure 
The Markov structure is used in Papers III–IV. A simple form is illustrated in Fig 4A. It allows 
more complexity and a longer time horizon compared with the decision tree. In Papers III–IV a 
10-year period was used; such a long simulation by a decision tree would require a large number 
of branches, which is difficult to handle and visualize. The circles in the Markov structure 
  10 
represent health states associated with clinical outcomes. The arrows show possible transitions 
through the model during a Markov cycle and are characterized by probabilities. 
 
 A    B 
Fig. 4. A. Illustration of a Markov structure.  
           B: The principle of how to apply the probabilities in each Markov cycle. 
 
As with the decision tree, the likelihood of each consequence is expressed as a probability and 
each consequence has a cost (C) and a health outcome/effect (E). These are allocated in the 
model where they occur. How the probabilities are used in a Markov structure is illustrated in 
Fig. 4B. During intervals of equal length (referred to as the Markov cycle) the individuals 
make transitions from one health state to another by the determined probability of transition. 
The cycles can be repeatedly applied and the expected costs and outcomes are accumulated at 
the end of the simulation. 
In deterministic analyses point estimates are used (mean values or other estimates), and in 
probabilistic analyses probability distributions are defined in both model structures. 
 
3.2.3 Handling uncertainty 
All cost-effectiveness analyses are associated with uncertainty, as costs and effects can never 
be predicted with complete precision. Paper II is a combined analysis using both model and 
collected individual data alongside a clinical trial. The uncertainty of costs is handled by t-test. 
In Papers I and III the term data uncertainty is used; such uncertainty is handled by sensitivity 
analyses in order to investigate the influence of these parameters on the results (Papers I and 
III). The steps of the sensitivity analysis are i) to identify the most relevant uncertain 
parameters and ii) to specify a plausible range of the parameters that are tested. One-way 
sensitivity analyses are used, that is when the estimates of each uncertain parameter of interest 
are varied one at a time. The data uncertainty has different sources. First, in early cost-
effectiveness analyses of unproven new interventions with lack of clinical data, estimates based 
on empirical or theoretical knowledge can be used (Paper III). Second, imprecise data may be 
available, as for example, when price lists are used as estimates of the hospital costs (Papers I 
and III). Third, methodological controversy may be incorporated into the model; one example 
is the use of pain intensity at rest as outcome; it can be discussed whether the most valid 
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measure of pain is obtained at rest or during activity (Paper I). Last, the input parameters may 
characterize specific clinical settings and the generalizability of the results may be explored by 
adjusting these parameters (Paper I). 
The term data uncertainty has to be distinguished from term parameter uncertainty, used in 
Paper IV. The term parameter uncertainty in modelling is related to the definite value that can 
be known with a certain precision for a particular population, and where more precision can be 
achieved by increasing the number of observations. It does not cover heterogeneity and 
variability. The heterogeneity relates to differences between patients that can be explained by 
age, sex, or comorbidity. Variability is the natural variation between individuals, even if they 
have the same observed characteristics, and it cannot be reduced by increasing the number of 
observations.  
The parameter uncertainty is defined by probability distributions according to 
recommendations.
42
 Beta distribution is constrained on the interval 0–1 and is appropriate to 
define the distribution of QALY weights. Dirichlet distribution is a multivariate generalization 
of beta distribution and is used to define the uncertainty of mutually exclusive events, which 
means that the sum of probabilities is always 1.0. It is used for the transition probabilities. 
Gamma distribution is constrained on the interval 0 to positive infinity and is used to represent 
the uncertainty of cost data that are usually highly skewed. Lognormal distributions are 
appropriate to define the relative risk, because the relative risk is made up of ratios and the 
most natural way to handle the ratios is to transform these into a log form. 
 
3.3 ESTIMATION OF THE VALUE OF FURTHER RESEARCH 
The probabilistic model is a suitable framework to handle the uncertainty, as the input 
parameters are characterized by appropriate probability distributions. For the analysis a Monte 
Carlo simulation is used where the values of the input parameters are randomly drawn from the 
defined probability distributions 1000 times, generating 1000 estimates of costs and health 
outcomes in terms of QALYs (Paper IV). In Fig. 5 simulated incremental costs and effects in 
QALYs are illustrated when Treatment A is compared to B. The uncertainty of input 
parameters is propagated into output uncertainty. For the majority of the simulations Treatment 
A is better and less costly (lower right quadrant). If Treatment A were adopted, this decision 
would be uncertain because of the risk of taking „wrong decision‟. The „wrong decision‟ is the 
upper left quadrant in Fig. 5 and also those values in the upper right quadrant that are above the 
dotted line (λ) representing the cost-effectiveness threshold. The decision uncertainty is 
determined by the combined uncertainty of the model inputs. The probability of a wrong 
decision is quantified and the consequences of „making a wrong decision‟ are expressed as a 
monetary value.   
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Fig. 5. The difference of costs (∆Costs = CostA – CostB) are plotted against the difference of effects 
(∆QALY = QALYA – QALYB). For most of the model outputs Treatment A is better and less costly 
(lower right quadrant), for some it is better and more costly (upper right quadrant), and for others it is 
less effective and more costly compared to Treatment B (upper left quadrant). The slope of dotted line 
is the cost-effectiveness threshold. 
 
3.3.1.1 Calculation of the net benefit and incremental net benefit 
For each of the 1000 simulations the net benefit (NB) is calculated by: 
 
NB =  * E − C 
 
Where  is the cost-effectiveness threshold; E is the effect (measured by QALYs), and C is the 
cost of the treatment. 
The monetary value of making the „correct decision‟ between Treatments A and B is calculated 
by the incremental net benefit (INB) using the following equation: 
 
INB =  * (EffectA − EffectB) - (CostA − CostB) =  * E − C 
 
When the value of INB is >0, Treatment A is the „correct decision‟. 
 
3.3.1.2 Calculation of the expected value of perfect information 
The principles of the expected value of perfect information (EVPI) calculation are illustrated 
by the first five values of net benefits of a Monte Carlo simulation for Treatments A and B 
(Table 2, columns 2 and 3). Based on the mean results, the „correct overall decision‟ is to 
choose Treatment A, has the highest mean NB (€7000 vs. €6520). The mean incremental NB 
(column 4) is the benefit if Treatment A is chosen instead of Treatment B (€480). However, 
this decision is „wrong‟ in simulations 2 and 5, where Treatment B should be preferred. If 
perfect information were available, the net benefits for each simulation would be known and 
the wrong decision could be avoided. The improved values of NB given perfect information 
are averaged (€7120, column 5) and the gained benefit of the perfect decisions (€120, column 
6) is the EVPI. The EVPI is the mean net benefit given the perfect information (column 5) 
minus the mean net benefit of the preferred treatment given the current information (column 2).  
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Table 2. Example from the Monte Carlo simulation illustrating the net benefit, incremental net benefit, 
net benefit with perfect information and gained benefit with perfect information (the expected value of 
perfect information, EVPI) for treatments A and B 
Column 1 2 3 4 5 6 
Simulation Net benefit of 
Treatment 
Incremental 
net benefit 
A vs. B 
Net benefit 
with perfect 
information 
Gained net benefit 
with perfect 
information A B 
1 7000 6000 1000 7000 0 
2 6000 6500 -500 6500 500 
3 7800 6800 1000 7800 0 
4 7600 6600 1000 7600 0 
5 6600 6700 - 100 6700 100 
Mean 7000 6520 480 7120 120 
 MAX mean NB 
A vs. B 
  MEAN max NB 
A vs. B  
EVPI  
Column 5–Column 2 
 
The mean net benefit for both strategies is calculated by the model using the 1000 simulated 
values of costs and outcomes. The maximum values of net benefit are taken from each 
simulation and the mean value of these is calculated (Table 2; column 5: net benefit with 
perfect information). 
 
EVPI = MEAN max NB (A vs. B) – MAX mean NB (A vs. B) 
 
The MEAN max NB (A vs. B) is the situation of perfect information, column 5. The MAX 
mean NB (A vs. B) is the situation with the given current „imperfect‟ information, column 2. 
The EVPI provides the value of perfect information for each time as a whole when a decision 
has to be made for an individual patient. However the EVPI is available also to inform the 
management of all future patients, or of a certain population who stand to benefit from 
additional information over the expected lifetime of the treatment. Therefore, the so-called 
effective population has to be estimated, that is, the number of patients facing this decision 
uncertainty during a chosen time period (applying also a discount rate). The population EVPI 
is calculated by multiplying the EVPI by the effective population: 
 
Population EVPI = EVPIpatient * Effective population 
 
The EVPI can be interpreted as the maximum monetary value of further research. 
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4 STUDIES ON POSTOPERATIVE PAIN TREATMENT 
This chapter introduces the first two studies, which are an application of deterministic analytic 
modelling that represents the early phase of learning in health economic evaluation. The 
methods and results are presented separately, followed by a merged discussion and conclusion. 
Full details on model structure, data identification, and data incorporation are found in the two 
papers (Papers I and II), and further details on Paper I in a published report.
i
 
 
4.1 PAPER I. EVALUATION OF COSTS AND EFFECTS OF EPIDURAL 
ANALGESIA AND PATIENT-CONTROLLED INTRAVENOUS ANALGESIA 
AFTER MAJOR ABDOMINAL SURGERY 
Good postoperative pain treatment is a mandatory component of adequate postoperative care, 
particularly if accelerated recovery is an aim.
43-45
 The postoperative epidural analgesia (EDA) 
and patient-controlled intravenous analgesia (PCIA) were introduced in 1997 for major 
abdominal surgery at the University Hospital in Linköping (Sweden) and a local database was 
started for quality control. The first assessment of the effectiveness of EDA (1997–1999) 
confirmed the failure rate found by others.
21-23
 For 10 per cent of patients the epidural analgesia 
was unexpectedly discontinued because of technical problems, minor side effects, or 
insufficient pain relief. This clinical problem affects a large number of patients treated for 
postoperative pain in Sweden. 
 
4.1.1 Aims 
The primary aim is to analyse the cost-effectiveness of epidural analgesia compared with 
patient-controlled intravenous analgesia. A secondary aim is to assist the clinical choice 
between these two options, as according to the guidelines of the Swedish Society of 
Anaesthesiology, both methods are established alternatives following major surgery. 
 
4.1.2 Methods 
A decision analytic model on cost-effectiveness was developed to illustrate the clinical 
pathways for comparing EDA and PCIA. The cost-effectiveness is expressed by the 
incremental cost-effectiveness ratio, as outlined in Chapter 3.2. All costs were in 2005 prices 
and were converted to euros using the exchange rate 1 euro = 9 SEK. The model was 
programmed and analyzed using Microsoft Excel (Microsoft Corporation 1985–2001, version 
10.0.6856.0). 
The main data source was a local register of 644 consecutive patients treated with EDA 
(n = 602) or PCIA (n = 42) following major abdominal surgery. The compared alternative 
strategies were thoracic epidural analgesia (ropivacaine 2 mg ml-1 with morphine 0.03 mg ml-
1 by a constant volume pressure infuser at a rate of 5.5 ml/h) and patient-controlled 
intravenous analgesia (morphine 5 mg ml
-1
 by individually programmed pump). In the actual 
clinical settings the length of postoperative observation on the postoperative care unit/intensive 
care unit (PCU/ICU) was 12 hours for EDA and 3–4 hours for PCIA. 
                                                 
i
 Postoperativ smärtlindring - till vilket pris? En hälsoekonomisk modellanalys av två smärtlindringsmetoder. 
CMT rapport 2006:1: http://liu.diva-portal.org/smash/record.jsf?searchId=1&pid=diva2:254680. 
  
 
15 
The structure of the decision tree is shown in detail in Fig.2 (in Paper I); it illustrates the 
clinical pathways of completed treatment, change of treatment strategy, unsuccessful attempt to 
introduce epidural catheter, early dislocation of catheter, reinsertion of epidural catheter, and 
need for additional pain treatment. The probabilities of the selected pathways were extracted 
from the database. The measure of effect was the number of pain-free days at rest; the costs of 
human resources, medical devices, drugs, and postoperative care were quantified. The 
expected costs and effects were analysed using the decision tree, as described in Chapter 3. 
One-way sensitivity analyses were performed to handle the following data uncertainties: fixed 
price of the length of stay on PCU/ICU, the better analgesic effect of EDA over PCIA during 
activity, the technical failure of EDA that might characterize only the actual clinical settings, 
and the potential bias of a non-randomized data source. The influence of technical failure of 
EDA was tested by the „optimal scenario‟ analysis, where the probabilities for catheter 
dislocation, unsuccessful attempt, reinsertion of catheter, and change of treatment due to 
analgesic failure were reduced. The possible bias related to the non-randomized data was tested 
by a matching procedure: each PCIA patient was matched in a pair with one EDA patient, 
using first the age and type of surgical intervention and then the gender and ASA group (the 
five-category physical status classification adopted by the American Society of 
Anaesthesiologists). 
 
4.1.3 Results 
In the base case analysis the incremental effect (EDA vs. PCIA) is 0.19 pain-free days at rest, 
the expected incremental cost is €1 074. The cost per pain-free day at rest is €721/patient for 
EDA and €289/patient for PCIA; the ICER at rest is €5 653 (Table 3). The probability of 
achieving 3 pain-free days without any additional pain treatment and without any technical 
problem is 0.49 at rest and 0.41 during activity for EDA. The corresponding values for PCIA 
group are 0.56 at rest and 0.28 during activity (these values can be found in the decision tree in 
Fig.2 in Paper I). 
 
Table 3. The expected number of pain-free days (rest and activity) and the costs of postoperative 
epidural analgesia and patient-controlled intravenous morphine analgesia. The incremental effect, cost, 
cost-effectiveness ratio (CER), and incremental cost-effectiveness ratio (ICER) are calculated as 
described in Chapter 3 
  
Cost/patient 
 
€ 
Effect 
Number of pain-free days 
CER* 
Cost/pain-free 
day/patient 
€ 
 
Rest 
 
Activity 
EDA 1701 2.36 1.86 721 
PCIA 627 2.17 1.27 289 
Incremental EDA/PCIA* 1074 0.19 0.59 5653 (ICER) 
* For base-case analysis incremental effect at rest is used. 
 
The sensitivity analyses confirm that PCIA is the cost-effective alternative, even if the ICER is 
sensitive for some changes in the input parameters, and it varied between €1448–€4308 (Table 
4). 
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Table 4. Sensitivity analysis is performed to estimate the influence of uncertain items on the 
incremental cost-effectiveness ratio (ICER). The model was run using the lowest price of stay on the 
postoperative care unit (PCU), the higher incremental effect of epidural analgesia (EDA) over patient-
controlled intravenous analgesia (PCIA) during activity, an optimized scenario, and a matching 
procedure.  
 Base 
case 
Lowest price  
of PCU 
Pain at 
activity 
Scenario 
analysis 
Matching 
procedure 
 
Cost/patient for EDA 1701 992 1701 1666 1704  
Number of pain-free days 2.36 2.36 1.86 2.56 2.42  
EffectEDA – EffectPCIA 0.19 0.19 0.59 0.39 0.25  
ICER  5653 1448 1896 2664 4308  
 
 
4.2 PAPER II: COULD BENEFITS OF EPIDURAL ANALGESIA FOLLOWING 
THORACOABDOMINAL OESOPHAGECTOMY BE MEASURED BY 
PERCEIVED PERIOPERATIVE PATIENT WORKLOAD? 
Even if the postoperative epidural analgesia has poor cost-effectiveness, even if there is no 
evidence of benefit expressed by clinical or patient-oriented outcome in general surgical 
patients,
10,20
 and even if the statistically significant lower pain scores compared with 
intravenous analgesia do not reach a clinically appreciable superiority,
6,20
 the epidural 
analgesia is regarded as the gold standard. These facts induced the hypothesis of Paper II, 
namely, if ordinary measures of outcome cannot capture the benefits that give epidural 
analgesia its status as the gold standard, probably the caregiver experience, for example, 
nursing workload during the care of the patient, could affirm the supposed superiority. 
 
4.2.1 Aims 
The aim is to analyse whether the postoperative epidural analgesia may decrease the nursing 
workload and hence the costs of postoperative care. The hypothesis is that due to superior 
efficacy of EDA compared with intravenous analgesia influences the perceived perioperative 
workload following thoracoabdominal oesophagectomy. 
 
4.2.2 Methods 
This was a cost minimization analysis (Chapter 3). The costs were based on 2005 health care 
prices; the equivalent value of one euro was assigned nine SEK. 
The population of a published trial (n = 201) on patient-controlled epidural (n = 166) and 
patient-controlled intravenous analgesia (n = 35) following thoracoabdominal oesophagectomy 
was selected for this analysis. The trial was conducted at the University Hospital of Lund,
46
 
and a standard clinical pathway was used: the patients were postoperatively treated on the ICU. 
The ICU costs incorporate the length of ICU stay and scores using the Nursing Care Recording 
System,
47
 This scoring system measures the nursing workload associated with patient care and 
medical procedures. 
The compared strategies were patient-controlled epidural analgesia (PCEA: bupivacaine 
2.5 mg ml
-1
 and morphine 0.05 mg ml
-1
, at a rate of 1–5 ml/h-1; bolus doses of 1–5 ml, lockout 
interval of 30 minutes) and patient-controlled intravenous analgesia (PCIA: morphine infusion 
of 1–2 mg/h-1 and 0.5–2 mg bolus doses with a lockout interval of 10 minutes). The treatments 
were not randomly allocated, the choice was based on individual prerequisites with the primary 
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aim to use PCEA; both treatments were planned to run for 6 days and a standardized clinical 
pathway was used. 
Two strategies were used to analyse the costs: i) a decision tree model was used for the pain 
treatment procedures; ii) individual postoperative ICU costs were collected and analysed. The 
ICU costs were recorded and calculated by the Accounting Department in real time, but were 
extracted retrospectively for this analysis. The null hypothesis was tested by t-test. 
 
4.2.3 Results 
For the cost analysis, data on 132 patients are complete; the patient characteristics are similar 
in the two groups with the exception of a previous history of angina (Table 5). No differences 
in morbidity, time on ventilator, or ICU stay are found between the two groups (Table 6).  
 
Table  5. Patient characteristics for patient-controlled epidural analgesia (PCEA) and patient-controlled 
intravenous analgesia (PCIA), given as percentage (%) and number (n) when not stated otherwise. The 
data are extracted from the study of Rudin and colleagues. There are no significant differences found 
between the groups. 
Patient characteristics PCEA 
n = 110 
% (n) 
PCIA 
n = 22 
% (n) 
 
Age in years, mean (range) 64  (10)   64  (11)  
Female  26  (29) 42    (9)  
Male  74  (81) 58  (12)  
ASA I  29  (32) 14    (3)  
ASA II  57  (63) 72  (16)  
ASA III   14  (15) 14    (3)  
Previous MI  6    (7)  5   (1)  
Previous CHF  6    (7)  0   (0)  
Previous angina    5    (5) 18   (4)  
Previous COPD  7    (8)  5   (1)  
Diabetes mellitus   9  (10)  0   (0)  
MI: previous myocardial infarction, CHF: chronic heart failure, COPD: chronic obstructive pulmonary disease 
The estimated cost of pain treatment is €1 037 for PCEA and €410 for PCIA (Table 6). Patients 
given intravenous analgesia have a tendency to use more intensive care resources, representing 
a difference of €2350/patient (p = 0.33).  
 
Table 6. Postoperative data, the cost of pain treatment, and intensive care unit cost/patient (euros).  
Postoperative data PCEA 
n = 110 
PCIA 
n = 22 
p-value 
 
Postoperative respiratory complication 0.17 0.27 0.27  
Postoperative cardiovascular complication 0.09 0.18 0.21  
Postoperative intubation time, h 12.5 11.7 0.58  
Length of stay on the ICU, h (range) 30 (13–169) 28 (12–377) 0.73  
Cost of pain treatment  1 037    410 n.a.*  
Cost of ICU 5 571 7 921 0.33  
ICU: intensive care unit. * costs of pain treatment are expected cost per patient, are not sampled but deterministic 
data, calculated by a model analysis and T-test is not appropriate 
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4.3 DISCUSSION OF PAPERS I–II 
The main results are summarized as follows: 
1. The estimated cost of epidural analgesia is approximately 3 times higher than intravenous 
analgesia, independent of which kind of delivery system is used: fixed rate pressure-
volume device (Paper I) or patient-controlled pump (Paper II). 
2. One additional pain-free day costs €5 653 if epidural is compared with intravenous 
analgesia (Paper I). 
3. High-risk surgical patients treated by epidural analgesia have a tendency to use slightly less 
postoperative intensive care resources compared with intravenous analgesia, though no 
difference is found in the length of ICU stay (Paper II). 
 
4.3.1 The strengths of Papers I–II 
In the field of postoperative pain treatment no cost-effectiveness analysis was found in the 
literature that satisfies the requirements of a health economic evaluation. The most central tenet 
of evidence-based medicine is that the highest degree of evidence is extracted from 
randomized clinical trials. Using a decision tree, information in a clinical database is refined. 
1. The limited clinical effectiveness of EDA becomes prominent in the decision tree; this 
disadvantage of EDA is not reported in the randomized clinical trials. 
2. The uncertainty of data due to the non-randomized data source is handled by sensitivity 
analyses in the model. 
3. The consequences of the limited clinical effectiveness of EDA are quantified by the 
expected costs per pain-free day, placing the epidural behind the intravenous analgesia in a 
health economic context. 
 
Paper II situates the postoperative use of resources in the Swedish context. The selected 
population is suitable to assess the postoperative ICU costs, because no fixed prices are used. 
The lack of lower health care costs (based on t-test) is in line with findings of others.
13-16
 
However, it is a matter of interpretation whether the tendency to lower ICU costs using 
epidural analgesia is relevant or not. If the analysis addresses information on budget needs, the 
incremental cost of €2 350 Euros per patient (PCEA vs. PCIA) may become relevant if it 
considers a large number of high-risk surgical patients in Sweden.  
 
4.3.2 The limitations of Papers I–II 
The main limitations of both Papers are related to the use of non-randomized data sources, and 
these are discussed in detail in the Papers. Below, three further limitations are considered. 
1. The use of number of pain-free days as a measure of effect does not describe the patient‟s 
health, which is required for health economic evaluations. However, the use of any health 
outcome and the calculation of QALYs would be inappropriate, as the decision tree 
illustrates short-term consequences of treatment. This shortcoming prevents the 
comparison of the ICER across other diseases, and it cannot be related to the willingness to 
pay. 
2. It can be questioned whether the nursing workload could be transformed into ICU costs. 
The ICU costs are based on both nursing scores and length of ICU stay, but the latter may 
be influenced by attitudes instead of medical fitness, and therefore may shadow the impact 
of nursing scores on the ICU costs. Regardless of this drawback, the postoperative ICU 
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cost is a relevant measure, because reduced ICU costs are expected, especially for high-risk 
patients. 
3. A methodological limitation is that deterministic analyses are used instead of a 
probabilistic approach. Paper I is the first one of four studies on applying decision-analytic 
models in perioperative care, and the most fundamental analytic strategy was tested first. 
 
The robustness of the cost-effectiveness (Paper I) and of the cost analysis (Paper II) is not 
influenced by these limitations, and the higher costs of epidural analgesia are in line with 
others findings.
13-16,22,48,49
  
 
4.3.3 Implications for policy decisions 
Usually policy decisions at the clinical level are based on the evidence of efficacy.
50
 The 
presented analyses are aimed to assist clinical policy decisions by providing additional 
information on clinical effectiveness, cost-effectiveness, and the use of postoperative 
resources. 
In Sweden the patients have the right to choose a more expensive treatment if it is more 
effective. However, it could be debated whether the additional cost of €5 653 for pain-free days 
gained is reasonable when the cost of €55 000 per one life-year gained with full health is a 
concern for other interventions in Sweden. Another question for the clinical decision is who 
will suffer because of the lack of resources. The clinical budget is usually strained, and the 
allocation of human resources to ensure epidural analgesia for all kinds of major surgery may 
be challenged if the same resources could be used for other activities that are supported by 
evidence for improving the postoperative outcome. 
The present studies indicate that under clinical circumstances the patient-controlled 
intravenous analgesia is a cost-effective alternative following major abdominal surgery, and in 
high-risk patients (e.g. cases of thoracoabdominal oesophagoectomy), epidural analgesia may 
save postoperative costs. Bearing in mind that only high-risk patients following high-risk 
surgery may have benefit in clinical outcome from epidural analgesia, clinical pathways have 
to be designed to select the appropriate pain treatment strategy, also considering the optimal 
use of resources. 
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5 STUDIES ON HAEMODYNAMIC OPTIMIZATION 
Studies III and IV are presented separately, followed by a merged discussion. In the Appendix 
of this thesis further details of the decision analytic model used for cost-effectiveness analysis 
and the value of further research on haemodynamic optimization can be found. 
 
5.1 PAPER III. TIME FOR CLINICAL RESEARCH? GOAL-DIRECTED 
HAEMODYNAMIC TREATMENT OF ELDERLY PATIENTS WITH PROXIMAL 
FEMORAL FRACTURE IS PROMISING FROM A HEALTH ECONOMIC 
PERSPECTIVE 
The poor postoperative outcome of elderly patients following proximal femoral fracture is well 
known. In Sweden the postoperative four-month mortality is 15 per cent for females and 20 per 
cent for males, and only 50 per cent of patients are discharged to their original form of 
housing.
i
 There is growing evidence that perioperative fluid overload or deficit may contribute 
to increased postoperative morbidity and mortality.
51
 According to meta-analyses,
5,32,34
 a large 
number of trials on GDHT have been conducted on high-risk surgical patients, but only two 
small trials have addressed the benefit of GDHT in elderly patients following proximal femoral 
fracture. The current evidence for GDHT in elderly patients suggests that the length of hospital 
stay may be reduced, but this is not sufficient to support a decision to adopt the GDHT. Large 
longitudinal clinical trials are required, which address both clinical outcome and cost-
effectiveness, because all GDHT strategies are resource intensive. Given the cost and 
complexity of such a trial, a prior cost-effectiveness analysis could be done to estimate whether 
the GDHT may be worthwhile for elderly patients and to guide the initiation of a large trial. 
 
5.1.1 Aims 
The primary objective is to construct a decision analytic model
42
 to estimate the cost-
effectiveness of GDHT compared to traditional fluid treatment by synthesizing the currently 
available evidence in elderly patients before initiating a large clinical trial. The secondary 
objective is to direct the attention of researchers and financiers of clinical research to consider 
whether large, costly trials are reasonable on the elderly with proximal femoral fracture. 
 
5.1.2 Method 
A two-part model was developed: a decision tree for the postoperative short-term and a 
Markov structure for the long-term outcome (Fig1 A and B in Paper III). The model was fed 
with data from published trials
5,26,52
 and a wide range of Swedish data sources
ii
 (national 
registries and hospital administration) in order to estimate costs and health outcomes over a 10-
year horizon. As there was a lack of data on size of effect in elderly patients, the model was run 
according to prior estimates of effect size: i) first, published „baseline‟ values on relative risk of 
mortality and morbidity were used;
5
 ii) these were then increased stepwise between 25 and 90 
                                                 
i
 http://www.rikshoft.se/se/images/stories/arsrapporter/Arsrapport2008.pdf. 
ii
 Swedish National Register on Hip Fracture, Swedish National Stroke Registry, Swedish National Registry on 
Secondary Prevention in Cardiac Intensive Care (SEPHIA), Epidemiological Centre of the Swedish National 
Board of Health and Welfare, and the Accounting Departments of the Karolinska University Hospital, Huddinge, 
and of the University Hospital Lund. 
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per cent by taking into account the expected limited efficacy of GDHT due to age and co-
morbidities of elderly patients.
53
  
For sensitivity analyses two alternative scenarios were tested: 
1. The pre- and post-fracture quality-of-life weights were obtained from the general 
population,
54,55
 not from those with proximal femoral fracture, and the estimated 
postoperative QALYs could be overstated. For that reason the model was run by applying 
lower QALY weights. 
2. It is unclear which approach to GDHT should be used; one alternative is to extend the 
treatment in the postoperative period. For this reason the model was also run using a three-
fold increase of the perioperative costs of GDHT, assuming 12 hours of treatment in a 
postoperative care unit. 
 
The model structure (Fig. 1 in Paper III) and the identification and incorporation of relevant 
data are given in Paper III, and further details in the Appendix. The model was programmed 
and analyzed by Microsoft Excel (Microsoft Corporation 1985–2001, version 10.0.6856.0). 
 
5.1.3 Results 
When the estimated relative risk for morbidity is between 0.63 to 0.926 and for mortality is 
between 0.49 to 0.898, the GDHT is dominant compared with the traditional fluid therapy (less 
costly and better) on 75 years old hypothetical individuals, applying a 10-year horizon. When 
the relative risk for mortality and morbidity are 0.949 and 0.963, respectively, the GDHT may 
still influence the outcome by 0.068 QALYs gained, resulting in a reasonable ICER of €3 162 
per QALY gained (Table 7). 
 
Table 7. The mean health care costs, effects, incremental costs and effects, and the incremental cost-
effectiveness ratio (ICER) of goal-directed haemodynamic therapy (GDHT) and traditional fluid 
therapy. The model is run according to the baseline relative risk
5,26
 and the stepwise increased values of 
relative risk. The ICER is not expressed when the GDHT is dominant over the traditional fluid therapy. 
 Traditional 
fluid 
therapy 
GDHT* by estimates of relative risk for morbidity/ mortality 
Baseline 
0.63/0.49 
+ 25 % 
0.72/0.62 
+ 50 % 
0.82/0.75 
+ 60% 
0.85/0.80 
+ 80% 
0.93/0.90 
+ 90% 
0.96/0.95 
Costs €**  25 118 21 626 22 661 23 685 24 097 24 921 25 333 
Effect***   4.628 5.302 5.133 4.965 4.898 4.763 4.696 
∆Cost € †  -3 492 -2 457 -1 433 -1 021 -197 215 
∆Effect ††  0.674 0.505 0.337 0.270 0.135 0.068 
ICER
†††
  dominant dominant dominant dominant dominant 3 162 
* GDHT = goal-directed haemodynamic treatment, ** Cost = total direct health care cost in a 10-year period, 
*** Effect = QALY = quality-adjusted life-years,
† ∆Cost = CostGDHT – Costtraditional, 
†† ∆Effect = EffectGDHT – Effecttraditional, 
††† 
ICER = ∆Cost / ∆Effect 
 
The incremental costs are plotted against the incremental effects for all simulated values (Fig. 
6). 
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Fig. 6. The result of the simulations. The incremental effects (∆QALY) are plotted against the 
incremental costs (∆Costs, €). The model is run according to the baseline relative risk5,26 and the 
stepwise increased values of relative risk. 
 
When the model is run according to a higher degree of deterioration of postoperative health, 
the GDHT is still dominant up to an 80 per cent increase of relative risk (Table 8). The 
simulation with a three-fold increase of the perioperative costs results in the dominance of the 
GDHT up to a 50 per cent increase of relative risk (Table 8). 
 
Table 8. Results of the two scenario analyses. Incremental costs and effects and incremental cost-
effectiveness ratio (ICER) when goal-directed haemodynamic therapy (GDHT) is compared to 
traditional fluid therapy. 
  Relative Risk for morbidity/mortality 
Baseline + 25% + 50% + 60% + 80% + 90% 
Scenario 1* 
 
∆Cost, € -3 492 -2 457 -1 433 -1 021 -197 215 
∆QALY 0.710 0.532 0.355 0.284 0.142 0.071 
ICER dominant dominant dominant dominant dominant 3 028 
Scenario 2**  
∆Cost, € -1 929 -885 130 542 1 366 1 777 
∆QALY 0.674 0.505 0.337 0.270 0.135 0.068 
ICER dominant dominant 386 2 007 10 119 26 132 
* A 30% reduction of post-operative quality of life compared to what is reported in an age- and disease-matched 
general population from the Survey of Living Conditions in Sweden.
54,55
  
** Using a three-fold increase of cost of GDHT, assuming a 12-hour-long postoperative
 
monitoring. 
QALY = quality-adjusted life-years. 
 
5.2 PAPER IV. A NEW APPROACH TO INTERIM ANALYSIS OF A 
RANDOMIZED CLINICAL TRIAL. THE VALUE OF FURTHER RESEARCH 
ON GOAL-DIRECTED HAEMODYNAMIC THERAPY FOR ELDERLY 
PATIENTS. TRIAL NR (NCT01141894 CLINICALTRIALS.GOV) 
The prior cost-effectiveness analysis (Paper III) has shown that the GDHT may be cost-
effective within a wide range of estimated clinical effects. Both the lack of clinical outcome in 
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elderly patients and the predicted cost-effectiveness supported the initiation of a large clinical 
trial that was started in 2008. It is designed to test the hypothesis that goal-directed 
haemodynamic treatment will reduce postoperative complications in elderly patients (>75 
years) operated on for proximal femoral fracture. A sample size of 460 was calculated. A 
planned interim analysis on safety and efficacy was conducted after inclusion of 100 patients. 
Given the interim efficacy data, further data collection is required for statistical inference 
analysis and a further four years of recruitment is planned with a 12-month follow-up period. 
The predicted cost of the trial is high, and the estimate as to whether it is reasonable to proceed 
with further data collection is important for economic reasons. Is the additional information to 
be gained by further data collection worth the extra cost? The monetary value of further 
research is assessed by the analysis of the expected value of perfect information. 
 
5.2.1 Aim 
The aim is to estimate the expected value of perfect information (EVPI) based on incremental 
costs and health outcomes of GDHT vs. traditional fluid therapy, given the interim data on 
effect. 
 
5.2.2 Methods 
The EVPI analysis was done by further computation of the previously developed decision 
analytic model (Paper III).
42,56
 The model was updated with probability distributions for all 
input parameters for a probabilistic analysis. First a brief description of the clinical trial is 
given, and then data incorporation for the probabilistic analysis is presented. 
 
5.2.2.1 Outline of the randomized clinical trial on GDHT 
Design and objectives 
The study was a single-centre, open, randomized (1:1) and controlled, parallel-group 
superiority clinical trial, blinded for the data analyst; the length of follow-up was 12 months. 
Eligible patients (≥ 70 years, weight ≥40 kg) were those scheduled for operation of proximal 
femoral fracture during regular operating hours.
i
 The trial was approved by the Local Research 
Ethics Committee (ID: 2008–1240–31) and authorized by the Medical Products Agency (MPA 
ID; 151:2009/81083). The primary objective was to evaluate the postoperative morbidity at 
hospital discharge; the secondary objective was to evaluate the cost-effectiveness of GDHT vs. 
traditional fluid treatment.  
 
Interventions 
Prior to the trial a clinical programme was introduced to standardize the pre-, intra-, and 
postoperative supplementation of fluids and nutrition, the time between admission and 
operation, and the preoperative pain treatment. For both groups the lithium dilution cardiac 
output monitor (LiDCO, LiDCO Ltd., Sawston, Cambridge, UK) was used and spinal blockade 
was the preferred anaesthesia form. 
 
Goal-directed haemodynamic therapy 
Fluid challenge (3 ml/ kg
-1
) by colloid was given and was repeated if an increase of stroke 
volume (SV) by 10 per cent was achieved; if there was no increase, and if the oxygen delivery 
(DO2I) was < 600 ml ∙ min-1 ∙ m-2, an infusion of dobutamine was started at 0.2–10 g ∙ kg-
1∙min-1. The intervention was discontinued at the end of the operation. 
                                                 
i
 Further details are given at http://clinicaltrials.gov (a service of the U.S. National Institutes of Health). 
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The control group: traditional fluid therapy 
The algorithm of the traditional fluid therapy was identical to the previously introduced clinical 
programme: colloids (3–500 ml) before spinal anaesthesia, other fluids or vasoactive treatment 
(phenylephrine or ephedrine) for correction of decreasing blood pressure were given at the 
discretion of the attending anaesthesiologist. The LiDCO monitor was covered for the 
attending anaesthesia team. 
 
5.2.2.2 The decision-analytic model and data incorporation 
The model structure was identical to that described in Paper III and in the Appendix (Fig 2. in 
Paper IV). 
For all input parameters probability distributions were defined, with the exception of the long-
term health care costs (these were based on fixed prices) and long-term survival, which was 
extracted from large populations with low standard error. The model was updated by the 
interim data on relative risk of morbidity (GDHT vs. traditional fluid therapy). The interim 
mortality was low (n = 3) and could not be used in the model. Published valid mortality data in 
elderly patients using GDHT were not found. Therefore, point estimate of mortality was used: 
relative risk from high-risk patients was extracted from a recent meta-analysis (0.49),
5
 and it 
was reduced by 50 per cent (0.745). 
 
5.2.2.3 The expected value of perfect information 
The model was run using a Monte Carlo simulation and the EVPI analysis was performed as 
described in Chapter 3. The effective population, the number of patients who face the decision 
uncertainty, was 30 378 patients, allowing that there are 6 440 operations per year in Sweden 
(patients aged >79 years), and assuming that the decision is valid for 5 years and using a 3 per 
cent discount per year 
. 
5.2.3 Results 
The patient characteristics and the interim efficacy are given in Table 9. The procedure of 
inclusion is demonstrated in Fig. 1 (in Paper IV). 
 
Table 9. Patient characteristics and clinical outcome of the interim analysis. Values are absolute or 
mean ±SD 
Patient characteristics GDHT Traditional 
Number allocated 49 50 
Age, years (mean) 86 (±7) 85 ( ±7) 
Sex male/female 13/36 9/41 
American Society of Anaesthesiologists grading (1/2/3/4)  0/13/31/5 1/15/29/5 
Number of patients with complications 16 20 
Relative risk based on intention to treat (95% CI) 0.806  (0.464–1.397) 
CI: confidence interval 
The EVPI analysis was done as described in Chapter 3. At a cost-effectiveness threshold of 
€50 000 the value of perfect information is €407 per patient. At a cost-effectiveness threshold 
of €20 000 the EVPI per patient is €229. The population EVPI is between €6.9 million and 
€12.4 million, applying a cost-effectiveness threshold between €20 000 and €50 000. As 
explained in Chapter 3 the EVPI depends not only on the uncertainty of the input parameters 
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but also on the willingness to pay. The relationship between the cost-effectiveness threshold (λ) 
and net benefit (NB) is shown in Fig. 7. 
 
 
Fig. 7. The expected value of perfect information (EVPI) for a Swedish population aged 75–84 years 
with proximal femoral fracture. The EVPI is plotted against the willingness to pay (cost-effectiveness 
threshold). 
 
5.3 DISCUSSION OF PAPERS III–IV 
The GDHT is predicted to be cost-effective in elderly patients within a reasonable range of 
estimated relative risk for mortality and morbidity. If these estimates were accepted as likely 
estimates, the GDHT should be adopted. However, as there is a lack of valid efficacy and 
safety data on GDHT in elderly patients, clinical trials are required. The absence of GDHT 
trials in elderly patients can be explained by the fact that the comorbidity and high age could 
lead to doubts as to whether anything can be gained in elderly patients: „Implementation of any 
therapy will most probably not have any effect on mortality, as only 25–60 per cent of the 
mortality will be potentially susceptible to the intervention‟, due to the high age and 
comorbidities.
53
 Both the predicted cost-effectiveness of GDHT and the need of valid data on 
outcome in elderly patients were used in the application for funding of a large clinical trial. The 
trial is now ongoing and is funded by public resources. 
No published paper using the EVPI approach for interim analysis was found; however, in a 
broader perspective this type of analysis is increasingly used
57,58
 and discussed.
42,59,60
 Based on 
the EVPI analysis the statement that further research is required (based on efficacy) is now 
replaced by the statement that further research is potentially cost-effective, if the costs of the 
trial do not exceed the EVPI. It is important to see that the EVPI depends on the society‟s 
willingness to pay for a treatment. When the willingness to pay is low, the treatment is not 
expected to be cost-effective, the society will not adopt the treatment, and therefore additional 
research is unlikely to change this decision; thus, the EVPI is low. When the willingness to pay 
increases, the EVPI also increases, because the decision uncertainty increases (probability of 
„wrong decision‟) and the consequences of „wrong decision‟ are valued more highly. Of 
course, there is no such thing as perfect information, but the EVPI places a first hurdle to 
identify research that is potentially cost-effective and rule out research that will not be 
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worthwhile. The EVPI analysis may complement future applications for research funding of 
the ongoing trial. 
 
The risks of an interim analysis 
Sharing results of interim analyses could influence an ongoing trial, and it is suggested that 
results from an interim analysis should not be made public.
i,ii
 Further recruitment could be 
affected, as patients could be influenced by the preliminary efficacy data and reports of adverse 
events. Also, the risk of introducing bias into the ongoing trial could be substantial,
iii
 requiring 
adjustments of the sample size. The statistical approach to handling this problem will be 
detailed when results of the trial are reported in the future. The interim efficacy data are shared 
for several reasons: i) the GDHT algorithm has not previously been systematically used in aged 
patients and neither the safety nor the efficacy aspects of it are known and ii) the recruitment 
time has been prolonged unpredictably, as 65 of 187 eligible patients were operated on outside 
of the normal operating room hours (Fig. 1 in Paper IV). This also increased the cost of the 
trial and it is reasonable to address the value of further research, given the results of interim 
analysis. The trial should be considered as a „feedback trial‟;61 the awareness of safety, 
efficacy, and issues of further data collection due to the sample size are more important than 
the issue of secrecy. 
 
                                                 
i
 http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm127073.pdf. 
ii
 http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002928.pdf. 
iii
 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2279143/. 
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6 OVERVIEW OF THE STUDIES AND IMPLICATIONS 
Table 10. Summary of the hypotheses, methods, results, and conclusions in the presented papers 
 Epidural (EDA) vs. patient-
controlled intravenous analgesia 
(PCIA) 
Goal-directed haemodynamic therapy 
(GDHT) vs. traditional fluid treatment 
in elderly patients 
  Paper I Paper II Paper III Paper IV 
Hypothesis EDA is not cost-
effective  
EDA saves ICU 
costs  
GDHT is cost-
effective; clinical trial 
is indicated 
 
The value of 
further research is 
high 
 
Data source Clinical 
database 
Clinical trial National registries, 
published trials 
Interim data from 
the initiated  
randomized 
clinical trial* and 
national registries 
 
Time perspective Retrospective Retrospective Prospective Prospective 
 
Type of analysis Cost-
effectiveness 
Cost-
minimization 
 
Cost- 
effectiveness 
Expected value of 
perfect 
information  
 
Analytic strategy Decision tree Decision tree 
and clinical trial 
Decision tree and 
Markov structure 
 
Decision tree and 
Markov structure 
Measure of 
outcome 
Number of pain-
free days 
ICU costs QALYs QALYs 
 
 
Results EDA is not cost-
effective 
EDA does not 
save ICU costs 
GDHT is cost-
effective 
 
EVPI is high 
 
Conclusion The gold standard of EDA is 
questioned in a health economic 
perspective 
The prior cost-effectiveness analysis of 
GDHT supported the initiation of a large 
clinical trial.* The EVPI is high, given the 
interim analysis; further research is cost-
effective. 
* A randomized clinical trial on GDHT in elderly patients following proximal femoral fracture 
(http://clinicaltrials.gov). EVPI: expected value of perfect information, ICU: intensive care unit, QALY:quality-
adjusted life-year 
 
The papers in this thesis are unified by using analytic models for health economic evaluations, 
and in this chapter methodological aspects of using modelling are discussed. 
 
6.1 METHODOLOGICAL ISSUES ON MODELLING 
Clinical trials where health outcomes and costs are directly measured are considered to be the 
best tools for economic evaluation. This approach is applied in the ongoing randomized 
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clinical trial on effectiveness and cost-effectiveness of GDHT in elderly patients. The 
advantage of an RCT approach is the high internal validity, but the central role of an RCT in a 
health economic evaluation is questioned.
62
 The strongest indication for increasing use of 
modelling is a method guideline in the United Kingdom
i
 and a Swedish guideline for 
cardiovascular diseases.
ii
 It is argued that any framework for economic analysis has to address 
two key decisions in health care. One is whether or not to adopt a new intervention given the 
existing evidence, and the other is whether further evidence is needed to support this decision. 
For such an analysis accumulation of all available evidence is required, including the 
extrapolation of outcomes over an appropriate horizon of time; also, the decision uncertainty 
has to be quantified. These requirements make a single RCT as the only data source 
inadequate, and a single trial should be considered as only one of many sources of evidence. In 
this context the ongoing clinical trial on GDHT is not sufficient for a future comprehensive 
cost-effectiveness analysis, because evidence outside the scope of this trial also has to be 
integrated. Therefore, in a future cost-effectiveness analysis of GDHT, the developed model 
should be used and the ongoing RCT should represent only one of the relevant data sources. 
Papers I and II represent another aspect of the value of modelling. The decision analytic model 
as a framework makes it possible to analyse a large amount of information available in clinical 
databases and registries. These data offer additional knowledge, especially if there is a lack of 
relevant information on clinical effectiveness in the literature, or when trials are controversial 
due to previously made clinical policy decisions, and when these decisions need to be updated. 
 
6.2 THE FUTURE IMPLICATION FOR MODELLING 
EVPI analysis can be done over particular model parameters separately, by calculating the 
expected value of partial perfect information (EVPPI).
63
 The EVPPI analysis can be done, for 
example, over relative risk for mortality, morbidity, long-term survival, or long or short-term 
health outcome. With this analysis it is possible to identify which parameters contribute most 
to the decision uncertainty. For some input parameters the parameter uncertainty does not 
necessarily contribute to the decision uncertainty. If the EVPPI over parameters of interest is 
higher than the expected cost of the trial, further data collection is potentially cost-effective. If 
the EVPPI over a parameter is low, further data collection of this parameter is not cost-
effective, because increasing the precision of data will not contribute to the reduction of 
decision uncertainty. This information can be used for revision of the trial design; for example, 
in a future interim analysis the model can be updated not only by the interim data on relative 
risk but also on health outcomes. For parameters with high EVPPI, data collection from 
randomized clinical trial is cost-effective, while for those with low EVPPI, data collection from 
cohort trials or registries can be cost-effective. 
                                                 
i
 http://www.nice.org.uk/niceMedia/pdf/TAP_Methods.pdf. 
ii
 http://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/8592/2008-102-7_20081027_bilaga_2_rev1.pdf. 
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7 CONCLUSIONS 
 
Epidural analgesia is less cost-effective compared with patient-controlled intravenous analgesia 
and no saving of the postoperative intensive care costs can be achieved. Therefore, the position 
of epidural analgesia as a gold standard for postoperative pain treatment is challenged in the 
context of a broader decision-making perspective. 
 
A prior cost-effectiveness analysis of GDHT in elderly patients with proximal femoral fracture 
based on reasonable estimates of clinical effect shows that it may be cost-effective. This 
finding and the lack of valid outcome data on elderly patients supports the initiation of a large 
costly trial on the elderly patients. 
 
An interim efficacy and safety analysis of the clinical trial was conducted. The efficacy 
analysis indicates that further data collection is required; the analysis of the expected value of 
perfect information indicates that further data collection will be cost-effective. 
 
Understanding and performing health economic evaluations is beneficial for a clinician, 
because these evaluations are required for policy decisions in health care in a broader 
perspective; these evaluations can assist policy decisions on the clinical level, and furthermore, 
such analyses may be helpful in decisions on research funding. 
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8 APPENDIX 
The Appendix provides a more 
comprehensive outline of the model 
structure, alternative fluid treatment 
strategies, and data collection. It describes 
the data incorporation for the deterministic 
analysis in Paper III and for the probabilistic 
analysis in Paper IV. 
 
8.1 SHORT-TERM MODEL 
8.1.1 The structure of the decision 
tree 
The decision tree represents the short-term 
postoperative outcome for the traditional and 
goal-directed haemodynamic therapy 
(GDHT) following proximal femoral 
fracture (Fig. 1A in Paper III). The time 
horizon is 4 months. It starts with the 
decision (rectangle) between the two 
alternatives, followed by a circle (chance 
node) representing a point where alternatives 
events are possible. At this point the patients 
face a risk of complications of postoperative 
outcome. These alternative events are 
illustrated by branches coming out from the 
chance node representing the clinical 
pathways. The branches end at end nodes 
representing the selected postoperative 
complicated (stroke, cardiovascular or other 
complications, death) or uncomplicated 
outcome. These clinical pathways are 
mutually exclusive and are quantified by the 
probability of a particular postoperative 
outcome occurring at the chance node. The 
sum of probabilities following each node is 
1.0. The clinical pathways are quantified by 
health care costs (C) representing the cost 
per complication. The selected postoperative 
outcomes are quantified by health-related 
quality-of-life weights (QALY weights). 
 
 
 
 
8.1.2 Short-term outcome of 
traditional perioperative fluid 
treatment 
Randomized clinical trials in elderly patients 
with proximal femoral fracture using 
protocol-guided fluid optimization were 
searched in the literature. Two clinical 
trials
28,64,65
 and one meta-analysis were 
found. The clinical outcome of the 
traditional fluid treatment group was not 
used because of the small sample sizes.
65
  
Instead, postoperative outcome was 
extracted from the Swedish National 
Register on Hip Fracture on a cohort of 
patients (n = 402) operated on during the 
period 1 April 2003–31 March 2004 at the 
Department of Orthopaedics, Lund 
University Hospital, Sweden. The cohort 
had 100 per cent follow-up and the 
postoperative complications were obtained 
from individual hospital records, having 
daily visits during acute hospital stay, and a 
home visit at 4 months‟ follow-up. The 
cohort constituted a population of a 
consecutive trial on an evidence-based 
clinical pathway programme.
52
 The given 
perioperative fluid instructions included i.v. 
saline-acetate 0.5 L before spinal anesthesia; 
the systolic blood pressure should be kept at 
>2/3 of baseline or >90 mmHg.  
The cohort is considered as the best 
available data source to estimate the 
postoperative outcome of traditional fluid 
treatment because of the lack of a strictly 
guided perioperative fluid protocol and of 
stringent postoperative data collection. The 
postoperative outcome was obtained by 
personal communication (Hommel A, 
Thorngren KG). 
The probability of a particular postoperative 
outcome is expressed by the absolute risk 
(AR) using the following equation: 
 
 
 31 
 
ARtraditional = ncomplication / ntotal traditional 
where the ARtraditional is the risk for a 
particular complication, 
ncomplication is the number of observed 
complications, and 
ntotal traditional  is the number of patients in the 
cohort 
 
The number of complications was 
established as follows: patients with multiple 
complications having also stroke or 
cardiovascular (myocardial infarction or 
heart failure) complication were assigned as 
stroke or cardiovascular complications. No 
individuals had both stroke and 
cardiovascular complications. Patients with 
other complications, including pneumonia, 
renal failure, wound infections, deep-vein 
thrombosis, gastrointestinal bleeding, and 
confusion were assigned as other 
complications. The fatal outcome was 
assigned as death and did not contribute to 
any of the complications. In the 
deterministic analysis (Paper III) mean 
values of absolute risk were used. In the 
probabilistic analysis (Paper IV) Dirichlet 
distributions were defined, that is, a 
multivariate normalization of beta 
distribution that considers that the sum of 
probabilities of rival events is always 1.00 
(Table A1). 
 
8.1.3 Short-term outcome of GDHT 
The predicted transition probabilities in the 
decision tree for the individuals treated by 
GDHT are calculated by the following 
equation: 
 
ARGDHT = ARtraditional * RRGDHT/traditional 
where RRGDHT/traditional is the relative risk of 
morbidity/mortality (GDHT vs. traditional 
fluid therapy) and 
 ARtraditional is the absolute risk for traditional 
fluid therapy 
 
8.1.3.1 Data collection for the prior cost-
effectiveness analysis (Paper III) 
There are a large number of trials 
investigating the influence of the 
haemodynamic optimization of patients on 
the postoperative outcome. Generally, single 
trials are too small to find evidence on 
mortality; therefore, meta-analysis and 
systematic review articles were searched. 
Only reviews and meta-analyses on the 
clinical use of GDHT before the onset of 
organ failure were searched (1997–2010). 
The following searching strategy was used 
in the PubMed database: 
(("goals" [MeSH Terms] OR "goals" [All 
Fields] OR "goal" [All Fields]) AND 
directed [All Fields] AND ("haemodynamic" 
[All Fields] OR "hemodynamics" [MeSH 
Terms] OR "hemodynamics" [All Fields] 
OR "hemodynamic" [All Fields]) AND 
("therapy" [Subheading] OR "therapy" [All 
Fields] OR "therapeutics" [MeSH Terms] 
OR "therapeutics" [All Fields])) NOT 
("sepsis" [MeSH Terms] OR "sepsis" [All 
Fields]) NOT ("burns" [MeSH Terms] OR 
"burns" [All Fields] OR "burn" [All Fields]) 
Table A1. The estimates of postoperative short-term outcome (4 months) for traditional fluid 
treatment following operation on proximal femoral fracture at Lund University Hospital, Sweden, 
according to Hommel
52 
Outcome Absolute risk Standard error Dirichlet 
distribution 
No complications 0.398 0.024 (160, 242) 
Cardiovascular complications 0.065 0.012 (26, 376) 
Stroke 0.005 0.004 (2, 400) 
Other complications 0.403 0.024 (162, 240) 
Death 0.129 0.130 (52 350) 
Total 1.00   
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("fluid optimization" [All Fields]), ("oxygen 
delivery" [All Fields]) AND ("fluid" [All 
Fields]), ("fluid therapy" [All Fields]) 
Also, searches on author names and related 
articles were performed. 
 
 Mortality 
A summary of findings in meta-analyses and 
reviews is presented below
4,5,32,34,37,38,65
 
(Table A2). One meta-analysis on elderly 
patients with proximal femoral fracture was 
found, but the included trials were too small 
and mortality could not be used.
65
 Mortality 
from reviews and meta-analyses based only 
on oesophageal Doppler technique 
35,36,39
or 
dynamic haemodynamic variables needing 
controlled ventilation were excluded, 
because these technologies are not 
applicable in elderly patients who are mostly 
anaesthetized with regional blockade 
techniques. 
Clinical benefit can be achieved when 
GDHT is applied prior to the onset of organ 
failure
32-34
 and if the baseline mortality is 
high.
4,32
 These findings were confirmed in a 
more recent meta-analysis
5
 where a subset of 
analyses were performed to assess the effect 
of 
1. treatment before vs. after the onset of 
organ failure 
2. haemodynamic goals proposed by 
Shoemaker
40
 vs. other haemodynamic 
goals 
3. methodological quality using a validated 
quality scoring system
66
 
 
Table A2. The identified meta-analyses and systematic reviews on GDHT. Further details on 
exclusion of meta-analyses with approaches of GDHT that are not practical in elderly patients are 
detailed above  
Author, (year),  
number of 
patients 
Type of 
operation 
Before 
organ 
failure 
(yes, no 
mixed†)  
Haemodynamic 
goals proposed 
by Shoemaker 
Mortality Mortality 
rate of 
control 
group 
Risk 
reduction 
 
(p-value) 
Relative 
risk 
(95% CI) 
Odds 
ratio  
(95% CI) 
Boyd (1999)4 
n = 994 
Mixed Yes Mixed goals  0.35 
(0.23–0.53) 
Mixed  
Boyd (1999)4 
(subset*) n = 451 
Mixed Yes Mixed goals  0.25 
(0.15–0.43 
>10%  
Boyd (1999)4 
(subset*) n = 543  
Mixed Yes Mixed goals  0.88 
(0.39–2.00) 
<10%  
Kern (2002)34 
(subset*) n = 612 
Mixed Yes Yes Not 
calculated 
Not 
calculated 
>20% -0.23 ± 0.07 
(<0.05) 
Kern (2002)34 
(subset*) n = 500 
Mixed Mixed† Yes Not 
calculated 
Not 
calculated 
<15% -0.04 ± -
0.025 
(<0.05) 
Boyd (2003)32 
n = 1974 
Mixed Yes Mixed goals  0.45 
(0.33–0.6) 
Mixed  
Poeze (2005)5 
n = 5 733 
Mixed Mixed† Mixed goals 0.75 
(0.62–0.9) 
0.61 
(0.46–0.81) 
Mixed  
Poeze (2005)5 
(subset*) n = 4 174 
Mixed Yes Mixed 0.66 
(0.54–0.81) 
0.43 
(0.28–0.66) 
Mixed  
Poeze (2005)5 
(subset*) n = 1 142 
Mixed Yes Yes 0.49 
(0.36–0.65) 
0.41 
(0.29–0.59) 
Mixed  
Poeze (2005)5 
(subset*) n = 3 032 
Mixed Yes Mixed goals 0.84 
(0.64–1.10) 
0.83 
(0.62–1.11) 
Mixed  
Price (2007)65 
n = 130 
PFF** Yes No  1.44 
(0.45–4.62) 
<10%  
Giglio (2009)38 
 n = 3 410 
Mixed Yes Mixed goals  Missing***   
Rahbari (2009)37 
(subset*) n = 288 
Colorectal Yes Mixed  0.33 
(0.03–3.17) 
  
* subset: a subgroup analysis of the total number of patients included in the meta-analysis, ** Proximal femoral fracture, 
*** Major and minor gastrointestinal complications are given. † Mixed population with the use of GDHT both before and 
after the onset of organ failure 
CI: confidence interval. 
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Trials using goals other than those proposed 
by Shoemaker and goals applied after the 
onset of organ failure had no effect on 
mortality.
5
 The mean score on the 
methodological quality assessment was 9.1, 
which is 51 per cent of the maximal score of 
16. No correlation was found between the 
quality score and the odds ratio for the 
individual trials.  
The baseline value of 0.49 for relative risk 
(RR) of mortality (95% CI, 0.36–0.65) was 
extracted from the subset of trials where 
GDHT described by Shoemaker was used 
before the onset of organ failure. The 
disadvantage of the data is that the effect 
size may not necessarily be generalized to 
elderly patients. 
 
Morbidity 
The result of the literature search is 
summarized in Table A3. 
Two early trials
28,64
 on elderly patients were 
found; both had length of hospital stay as 
primary endpoint. In the trial of Sinclair no 
data on mortality and morbidity are reported. 
In the trial of Venn only a tendency to 
Table A3. The search result on trials which used GDHT before onset of the organ failure 
 
Author  
 (year)  
number of 
patients 
Haemodynamic goals 
(Monitoring techniques/ 
use of inotropic support) 
Type of 
operation 
GDHT before 
onset of organ 
failure 
yes/no 
Primary 
endpoint 
Relative risk of 
morbidity 
(95% CI) 
 
Absolute risk or 
incidence (%) of 
complications 
GDHT vs. Controll 
(p) 
Sinclair64 
(1997)  n=40 
Blood flow, SV, 
(OD) 
Proximal 
femoral 
fracture 
Yes LOS Not reported Not reported 
Wilson67 
(1999) n=138 
Oxygen delivery index 
(PAC / dobutamine or 
adrenaline) 
Major mixed  Yes LOS Odds: 0.30 
(0.11-0.50)* 
Not reported 
Takala68 
(2000) n=412 
Oxygen delivery index 
(PAC / dopexamine) 
Major 
abdominal 
Yes Mortality  No difference 
Lobo69 
(2000) n=37 
Oxygen delivery index 
(PAC) 
Major 
abdominal 
Yes Morbidity RR: 0.47 
(0.226-0.991) 
 
Gan70 
(2002) n=100 
Blood flow, SV 
 (OD) 
Major 
abdominal 
Yes LOS   
Venn28  
(2002) n=90 
CVP or blood flow, SV 
 (OD) 
Hip fracture Yes LOS   23% for CVP 
26% for OD vs. 49% 
p=0.078 
Conway71  
(2002) n=57 
Blood flow, SV 
 (OD) 
Colorectal Yes Cardiac 
Output 
Not reported Not reported  
Sandham72 
(2003) n=1994 
Oxygen delivery index  
(PAC)  
Mixed  Yes Mortality, 
morbidity 
No difference No difference 
Pearse26  
(2005) n=122 
Oxygen delivery index 
(LiDCO) 
Major mixed Yes Morbidity RR: 0.63 
(0.46-0.87) 
 
Noblett27 
(2005) n=108 
Blood flow, SV 
 (OD)  
Colorectal Yes LOS  2% vs. 15% 
(p=0.043) 
Donati29 
(2005) n=135 
Oxygen extraction rate 
Arterial and central 
venous line 
Major 
abdominal 
Yes Organ 
failure, 
ICU care 
 11.8% vs. 29.8% 
(p<0.005) 
Wakeling73 
(2005) n=128 
Blood flow, SV 
 (OD) 
Colorectal Yes LOS  37.5% vs. 59.3% 
(p=0.013) 
Lobo74  
(2006) n=50 
Oxygen delivery index 
(PAC / Dobutamine) 
Major 
abdominal 
Yes Morbidity  16% vs. 52% 
(p<0.05) 
Lopes75 
(2007) n=33 
PPV 
(IBPplus, Dixtal) 
Major 
abdominal 
Yes LOS  75 % vs.  45% 
(p=0.049) 
Senagore76 
(2009) n=64 
Blood flow, SV 
 (OD) 
Laparoscopic  Yes LOS  No difference 
Mayer77 
(2010) n=60 
SVV  
(Flotrac, vigileo) 
Major 
abdominal 
Yes LOS  20 % vs.  50% 
(p=0.001) 
Benes31  
(2010) n=120 
SVV 
(Flotrac, vigileo) 
Mixed high 
risk 
Yes Morbidity RR: 0.518 
(0.331-0.8) 
30% vs. 58.3% 
(p=0.0033) 
CVP: central venous pressure, CI: confidence interval, ICU : intensive care unit, LOS: length of hospital stay, OD: oesophageal 
Doppler, PAC: pulmonary artery catheter, PPV: pulse pressure variation, SV: stroke volume, SVV: stroke volume variation 
*Dopexamin vs. control 
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decreased short-term postoperative 
morbidity was found, which possibly could 
be attributed to the small population (n = 
90). Data from these trials could not be 
extracted. 
We aimed to obtain the RR of postoperative 
morbidity from comparable trial conditions 
to those that were used in the meta-analyses 
on mortality. A large number of trials were 
identified using different monitoring 
techniques and goals (Table A3).
26-29,31,64,67-
77
 The criteria for selection of input data in 
the model were: 
1. Use of a haemodynamic monitor and 
variables that can be applied in the 
clinical practice to elderly patients 
during spinal anaesthesia; all trials using 
oesophageal Doppler, or needing central 
venous line and/or mechanical 
ventilation, were excluded. 
2. Primary end-point is expressed by 
relative risk or absolute risk and/or 
incidence of postoperative 
complications. 
3. GDHT started before the onset of organ 
failure. 
 
Only one trial was identified.
26
 In this study 
the authors used the GDHT on the intensive 
care unit postoperatively. 
 
8.1.3.2 Prior estimates of mortality and 
morbidity (Paper III) 
The relative risk of neither mortality nor 
morbidity can directly be applied in the 
model for several reasons. 
1. In the early observational trials, 
Shoemaker described a relationship 
between outcome and various 
cardiovascular parameters on patients 
following high-risk surgery. Survivors 
consistently had higher cardiac index 
(>4.5 l/min/m
2
), oxygen delivery (>600 
ml ∙ min-1 ∙ m-2), and oxygen 
consumption (>170 ml ∙ min-1 ∙ m-2) 
compared to non-survivors.
40
 These 
values were chosen as cut-off points to 
test the hypothesis that in critical 
situations survivors have higher values 
of oxygen transport compared to non-
survivors. The cut-off values have been 
tested in a large number of randomized 
trials as goals for haemodynamic 
optimization. 
2. However, the goals are not adjusted to 
possible different needs as affected by 
age, comorbidity, level of surgical stress, 
and past haemodynamic deficit.
34
 There is 
a lack of data on which GDHT approach 
may achieve any benefit in elderly 
patients. There are GDHT strategies using 
other goals than those proposed by 
Shoemaker. These may have lower 
clinical benefit.
5
  
3. Due to the comorbidity and high age of 
elderly patients, only a part of the 
postoperative morbidity may 
hypothetically be influenced.
53
  
In order not to overestimate the benefits of 
GDHT in elderly patients, the extracted 
values of RR for mortality (0.49) and 
morbidity (0.63) were considered as 
„baseline‟ values and were stepwise 
increased by between 25 and 90 per cent, 
yielding hypothetical point estimates of RR 
in elderly patients (Table A4). 
The following equation was used: 
 
RR estimate = RR + (1 – RR ) * 0.25 . . . (* 
0.50 . . . * 0.90)  
RR estimate is the point estimate of relative 
risk mortality/morbidity. 
RR is the relative risk of mortality/morbidity 
obtained from meta-analysis
5
 and clinical 
trial.
26
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8.1.3.3 Estimates of mortality and 
morbidity, given the interim 
analysis (Paper IV) 
The relative risk of morbidity was obtained 
from the interim analysis of the ongoing 
randomized clinical trial (NCT01141894 
ClinicalTrials.gov). The number of patients 
was 49 in the GDHT and 50 in the 
traditional group. One patient in the GDHT 
group was assigned two randomization 
numbers: first the patient was excluded 
because of logistical reasons related to 
unplanned changes in the operation list and 
then was re-included next day. The relative 
risk of morbidity was based on intention to 
treat and calculated by the number of 
patients with one or more complication or 
fatality during the acute hospital stay. 
Lognormal distribution was defined (Table 
A5). The relative risk for mortality could not 
be estimated from the interim data because 
of the low number of observations (in-
hospital fatality was three). The relative risk 
of mortality was estimated by 50 per cent 
reduction of relative risk extracted from the 
same meta-analysis
5
 that was used in the 
prior cost-effectiveness analysis (Table A5).  
8.1.4 Quality of life 
A number of instruments have been 
developed to measure health-related quality 
of life (HRQoL), classified by either generic 
or disease-specific instruments. One of the 
generic HRQoL instruments is the EQ-5D.
78
 
This is a general quality-of-life instrument 
that divides health status into five 
dimensions: mobility, self-care, usual 
activities, pain/discomfort, and anxiety/ 
depression. Each dimension is divided into 
three degrees of severity: no problem, some 
problems, and major problems. The five 
health dimensions give 243 (i.e. 3
5
) 
separated health states. There are different 
methods of assigning value to the health 
states. One of them is the time trade-off, 
based on the valuation of a general 
population that assigns a single value index 
for each health state. Since there is no 
Swedish tariff the UK EQ-5D index tariff 
constructed in the United Kingdom was 
used. In the papers and the Appendix the 
term QALY weight is interchangeable with 
the EQ-5D index tariff. 
In a recent Swedish survey on osteoporosis 
the pre-fracture quality of life was assessed 
after the fracture by EQ-5D on patients with 
Table A4. The hypothetical estimates of relative risk for postoperative mortality and morbidity of 
goal-directed haemodynamic therapy compared to traditional fluid treatment in routine care  
 Estimates of relative risk  
Baseline + 25% + 50% + 60% + 80% + 90% 
Morbidity 0.63  0.723 0.815 0.852 0.926 0.963 
Mortality 0.49  0.618 0.745 0.796 0.898 0.949 
 
 
Table A5. Estimates of postoperative outcome expressed as relative risk of postoperative mortality 
and morbidity in Paper IV. The morbidity was obtained from the current clinical trial 
 Relative risk 
mean 
95% Confidence 
interval 
Lognormal 
distribution 
Postoperative morbidity 0.806 0.464–1.397 -0.216, 0.281 
Postoperative mortality* 0.745 Point estimate  
* The mortality was obtained from meta-analysis5 on other high-risk patients and reduced by 50 percent. 
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proximal femoral fracture (n = 283).
79
 This 
could lead to some bias, since the pre-
fracture health status may have been 
perceived as better than it actually was. The 
mean QALY weight was 0.81 (0.78–0.83).  
In the Survey of Living Conditions in 
Sweden for individuals at age 70–79 years 
the mean QALY weight was 0.79.
54
 The 
latter was chosen as the pre-fracture value in 
Paper III. In Paper IV, pre-fracture values 
for patients >80 years were used, because 
the mean age of the patients in the interim 
analysis was >80 years. As there is lack of 
direct QALY weights related to the selected 
postoperative complications, the following 
approach was used. Disease-related QALY 
weights were extracted; for individuals with 
cardiovascular complication or stroke, 
QALY weights of the general population 
with ischemic heart disease or stroke were 
used.
55
 To estimate the influence of „other 
complications‟ on health, the QALY weight 
of the general population with „moderate to 
severe‟ health problems was used.55 For 
individuals with fatal outcome, the QALY 
weight was 0. 
The QALY weight is the measure of 
outcome in the decision tree at the actual 
node. This is how the decision tree provides 
a bridge between the postoperative 
complications and the health-related quality 
of life. For the deterministic analysis, mean 
values were used (Paper III); for the 
probabilistic analysis (Paper IV) probability 
distributions were used (Table A6). 
 
8.1.5 The short-term costs 
The costs are expressed in euros (1 euro is 
equivalent to 9.41 SEK). 
 
8.1.5.1 Perioperative costs 
The costs of personnel, medical devices, and 
pharmaceuticals used for each fluid therapy 
were quantified. 
The lithium dilution cardiac output monitor 
(LiDCO, LiDCO Ltd., Sawston, Cambridge, 
UK) was the monitor considered for GDHT. 
The monitor needs arterial and a peripheral 
venous line. The cardiac output (CO) is 
measured by a beat-to-beat estimate of 
stroke volume and CO derived from the 
arterial pressure waveform. It requires an 
initial calibration with lithium chloride (0.3 
mmol/2 ml) as an indicator. 
To quantify the cost of personnel, time 
devoted to activities that could not be used 
simultaneously for other activities was 
measured and estimated (Table A7). It 
includes the preoperative optimization, the 
intraoperative interventions, and the 
postoperative visit on the postoperative unit. 
If the GDHT continued in the post-operative 
period, it would consume more resources. In 
a scenario analysis an alternative was tested, 
assuming an intervention of 8 hours‟ 
duration. 
 
 
Table A6. QALY weights and decrements used in the model with the defined distributions 
QALY weights and decrements Mean Standard Error Distribution 
QALY weights    
     Pre-fracture 70–79 years age   0.79 0.012  Beta (901, 234) 
     Pre-fracture >80 years age   0.74 0.021  Beta (322, 113) 
Recovered after other         
complication 
  0.66 0.025  Beta (227, 117) 
Decrements of QALY weights     
    After cardiovascular complications -0.19 0.011 Gamma (298, 0, 0006) 
    After stroke -0.35 0.035 Gamma (100, 0, 0035) 
    State after other complications -0.15 0.010 Gamma (225, 0, 0007) 
QALY = quality-adjusted life-year 
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The personal cost per hour for the staff, and 
costs of devices, was obtained from the 
Accounting Department in the Karolinska 
University Hospital, Huddinge, Sweden. The 
itemized costs are presented in Table A8. 
 
8.1.5.2  Costs of hospital stay 
Individual costs were obtained from the 
University Hospital, Lund, on the cohort of 
patients that was previously presented in the 
section on „Short-term outcome of 
traditional perioperative fluid treatment‟. 
The Accounting Department collected 
individual cost data on each of the 
hospitalized patients. The hospital costs 
included the following items. 
 
1. Cost per patient: a template of cost per 
bed-day is multiplied by the length of 
hospital stay. The template unit cost per 
bed-day is calculated by the hospital 
Accounting Department, based on the 
total costs per previous year and bed-
days on the actual ward. 
2. Cost of operation, reoperation 
3. Cost of intensive care 
4. Cost of laboratory tests 
5. Cost of microbiology culture 
6. Cost of radiology 
7. Cost of clinical physiology 
 
To estimate the cost per complication, the 
same grouping approach was used as was 
presented in the section on „Short-term 
outcome of traditional perioperative fluid 
treatment‟. Costs for patients having 
multiple complications in combination with 
cardiovascular complication or stroke were 
grouped as cost per patient of cardiovascular 
complication or stroke. Cost for patients 
having multiple complications or fatal or 
uncomplicated outcome contributed to cost 
per patient of other complications, of death, 
or of uncomplicated outcome, respectively. 
The mean costs used in Paper III and the 
probabilistic distributions in Paper IV for 
each complication are presented in Table 
A9. 
Table A7. Estimated time for activities for each fluid therapy that cannot be used simultaneously for 
other activities 
 
Activity 
Estimated time 
(minutes) 
 
Traditional fluid 
 
 
GDHT 
 
 
Scenario of longer treatment     
for GDHT 
Calibration and start of monitoring  0   54              54 
Activities for intervention 30 240            720 
GDHT: goal-directed haemodynamic therapy. 
Table A8. The most relevant perioperative cost items (Karolinska University Hospital, Huddinge) 
                           Cost items GDHT 
(€) 
Traditional fluid 
(€) 
Personal cost per patient in the preoperative area  159                27 
Personal costs (nurse, physician) for optimization 401              117 
Medical device (arterial line, device for calibration) 181 11 
Monitor (LiDCO) (5-year depreciation period)   40   0 
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8.1.6 Key assumptions in the 
decision tree 
The selected complicated clinical outcomes 
were death, cardiovascular (myocardial 
infarction, heart failure), stroke, and other 
complications. Other complications include 
pneumonia, kidney failure, wound 
infections, postoperative delirium, 
gastrointestinal bleeding, deep-vein 
thrombosis or pulmonary embolism. It 
would be possible to present all of these 
complications by separated branches, but in 
the real life patients have multiple 
complications. The decision tree, as 
mentioned above, only allows mutually 
exclusive transitions through the pathways, 
that is, the hypothetical individuals cannot 
move along two or more pathways 
simultaneously. The purpose of the model 
was not to trace the chain of the 
pathophysiological consequences of 
particular postoperative events, but to 
estimate the influence of the complications 
on the postoperative quality of life. For these 
reasons a choice had to be made as how to 
simulate the influence of the postoperative 
complications on the patient‟s health. 
1. An assumption was made that the non-
fatal cardiovascular complications and 
stroke may have the highest impact on 
health and health care costs for elderly 
patients. 
2. The hypothetical individuals with non-
fatal cardiovascular complications or 
stroke could not have multiple 
complications. This assumption may 
lead to an overstated postoperative 
quality of life in the model, and for this 
reason the model was run according to 
scenario analysis using lower quality-of-
life weights postoperatively. 
3. The same value of relative risk of 
morbidity was employed for each of the 
non-fatal postoperative complications, 
that is, the assumption was made that the 
GDHT influences each of these 
equivalently. Currently there are no data 
on relative risk of morbidity for each of 
the selected postoperative complications. 
 
Table A9. Mean and the probability distributions of costs per complication during the acute hospital stay 
Cost items Mean costs 
(€) 
Standard 
error 
Distributions 
        No complications 6 753 218 Gamma (967, 7) 
        Cardiovascular complications    
                   Myocardial infarction 7 498 791 Gamma (90, 83) 
                   Heart failure 9 903 971 Gamma (104, 95) 
       Cerebrovascular complication, stroke 7 550   
       Other complications    
                   Pneumonia 8 514 829 Gamma (106, 81) 
                   Renal failure 12 197 4194 Gamma (8, 1442) 
                   Wound infection 8 566 580 Gamma (218, 39) 
                   Deep-vein thrombosis 7 617 970 Gamma (62, 124) 
                   Pulmonary embolism 10 190 2472 Gamma (17, 600) 
                   Gastrointestinal bleeding 9 900 1235 Gamma (64, 154) 
                   Confusion 7 961 270 Gamma (866, 9) 
         Death 9 020 545 Gamma (273, 33) 
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8.2 LONG-TERM MODEL 
8.2.1 The Markov structure 
The model constructs a simplified course of 
diseased or recovered individuals after the 
hospital discharge (Fig.1B in Paper III). The 
circles represent health states associated with 
the complicated or uncomplicated 
postoperative outcome. The arrows show 
possible transitions through the model 
during a Markov cycle. One cycle is one 
year long and 10 cycles were applied.  
For individuals with cardiovascular 
complications or stroke the model allows the 
patient to stay in the diseased health state or 
to make the transition to death. Individuals 
with multiple complications may stay in the 
same health condition, or they may recover 
or make the transition to death. The 
recovered individuals may stay in the same 
health state or make the transition to death.  
At the start of the analysis the proportion of 
patients in the various health states is 
provided by the decision tree. 
 
8.2.2 Long-term postoperative 
outcome 
8.2.2.1 Survival after cardiovascular 
complication 
Mortality associated with cardiovascular 
complication was obtained by personal 
communication from the Swedish National 
Register on Secondary Prevention in Cardiac 
Intensive Care (SEPHIA). In recent years 
nearly 100 per cent of all cardiovascular 
events were reported to the register. One to 
three years‟ risk of mortality following 
myocardial infarction in individuals >70 years 
was employed in the model (Table A10). 
After the first three Markov cycles standard 
mortality was used. 
 
8.2.2.2 Survival after stroke 
One-year risk of mortality following stroke 
was obtained from the Swedish National 
Stroke Register.  In recent years, data from 
83 per cent of Swedish hospitals are 
reported. After the first Markov cycle 
standard mortality was used (Table A10). 
 
8.2.2.3 Survival after other complications 
One-year risk of postoperative mortality of 
individuals having other complications and 
those who recovered having other 
complications was obtained from the same 
cohort of patients that was presented in the 
section on „Short-term  outcome of 
traditional fluid treatment‟ (Table A10). 
Also here, after the first Markov cycle 
standard mortality was used. The 
uncertainties of long-term survival extracted 
from SEPHIA and the Swedish National  
Table A10. Estimated mortality associated with the postoperative outcome. These parameters are 
used as point estimates 
Complication Mortality 
absolute risk 
Standard 
error 
Distribution 
Cardiovascular disease    
                                             In-hospital  0.057   
                                             1 year 0.107   
                                             2 years 0.058   
                                             3 years 0.056   
Stroke (1 year) 0.15   
Other complications within first year 0.18 0.029 Beta (31, 140 
After recovery from other complications, first year 0.15 0.037 Beta (17, 95) 
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Stroke Register were not defined; these were 
considered as point estimates, because they 
were drawn from large populations and the 
values of standard error were low. For 
estimates of outcome after other 
complications probability distributions were 
used because the values were obtained from 
the Swedish National Register on Hip 
Fracture for a cohort of patients (n = 402).  
 
8.2.3 Long-term quality of life 
Effects (QALYs) were discounted by 3 per 
cent annually. 
Pre-fracture and postoperative QALY 
weights related to cardiovascular 
complications, other complications, and 
stroke are presented in the short-term model 
(Table A6). For quality of life data on 
individuals who recovered during the first 
year after postoperative complication, a 
literature search on Swedish trials was 
conducted. Longitudinal trials on healed 
fractures and healing complications were 
found.
80
 We considered that the group of 
healed fractures might represent an estimate 
of QALY weights for individuals who 
recovered after having other postoperative 
complications. 
Using the pre-fracture and the complication-
related QALY weights, decrements of 
quality of life were calculated (Table A11). 
The postoperative QALY weights were 
allocated at the beginning of the first 
postoperative year at the start of the Markov 
structure and the yearly decrements were 
used for the diseased individuals, applying 
10 cycles. The disease-related QALY 
weights may be overstated for two reasons: 
1. They are not age-related but are based on 
the whole population (16–84 years). 
2. An assumption was made in the decision 
tree that the hypothetical individuals 
with stroke or cardiovascular 
complications could not have multiple 
complications. 
In the scenario analysis, therefore, QALY 
decrements increased by 30 per cent were 
used to allow more influence of the 
postoperative complications on the quality of 
life (Table A11). 
 
8.2.4 Long-term health care costs 
The costs are expressed in euros (1 euro is 
equivalent to 9.42 SEK). 
The direct health care costs included both in- 
and outpatient costs. 
A large Swedish prospective costing study 
(KOFOR) on osteoporotic fractures was 
launched 2002.
79,81
 Cost data from this study 
could not be used in the model because the 
mean of total community and health care 
costs per patient were reported and costs per 
complication were not separated. The 
approach to estimating the direct health care 
costs for each of the selected complications 
was as follows. 
The Epidemiological Centre of the Swedish 
National Board of Health and Welfare 
Table A11. QALY weights
54,55,80
 and decrements used in the Markov structure to estimate the 
quality of life associated with the postoperative outcome. 
Health states QALY weight QALY 
decrements 
Hypothetic 
QALY decrements 
for the scenario 
analysis 
Pre-fracture values (age 70–79 years)  0.79   
Recovery from other complications 0.66   
Cardiovascular complications 0.60 -0.19 -0.247 
Stroke 0.44 -0.35 -0.455 
Other complications 0.64 -0.15 -0.195 
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database was searched using the following 
criteria: 
1. All patients operated on for proximal 
femoral fracture during 2007 were 
selected (n = 16 800). 
2. Patients with the World Health 
Organization International Classification 
of Diseases codes related to myocardial 
infarction, cardiac failure, stroke, renal 
failure, pneumonia, wound infections, 
gastrointestinal bleeding, thrombo-
embolic events, and confusion were 
selected. Both hospital and outpatient 
costs during 2008 for the selected 
patients were extracted. 
3. Costs per patients were grouped using 
the previously described grouping 
approach for the postoperative 
complications. 
4. Mean cost per complication for hospital 
stay was calculated. 
5. Mean outpatient cost per complication 
was calculated. 
 
The health care cost for uncomplicated 
outcome was estimated by using the mean 
value of outpatient costs of the whole group 
of patients who received surgical treatment 
(Table A12). In the first Markov cycle both 
hospital and outpatient costs were allocated. 
In order not to overestimate the long-term 
health care costs, it was assumed that after 
the first year the patients had only outpatient 
costs. The cost of death after the acute 
hospital stay was obtained from the 
Accounting Department of the geriatric ward 
(Karolinska University Hospital, Huddinge). 
 
8.2.5 Assumptions in the Markov 
structure 
1. The hypothetical individual lives with 
the consequences of postoperative 
cardiovascular complications or stroke 
without recovery. As the hypothetical 
individuals are aged (>75 years), this 
assumption and simplification is 
reasonable. 
2. Individuals with other complications if 
they are non-fatal may recover. 
3. Individuals with cardiovascular 
complications have an increased risk of 
dying only during the first three years 
postoperatively. In the following years 
standard age-related mortality is 
assumed. 
4. Individuals with stroke have an 
increased risk of dying during the first 
year. In the following years the risk is 
comparable to standard mortality. 
5. During each cycle the individuals make 
transitions in the middle of the cycle at 
the same time, that is, mean values of 
transition probabilities are used. 
An assumption was made that the 
individuals having any of the postoperative 
complications had hospital care only during 
the first postoperative year. The following 
nine years only use of outpatients care was 
assumed. 
Table A12. Estimated health care cost items per patient per year for complicated and uncomplicated 
postoperative outcome (Epidemiological Centre of the Swedish National Board of Health and 
Welfare) 
Cost item Costs per patient per year 
in the first year  
(mean, €) 
Costs per patient per year 
after the first year  
(mean, €) 
Cardiovascular complication 7 673 386 
Stroke 7 512 402 
Other complications 7 314 396 
Uncomplicated outcome     147 147 
Death 4 837                       4 837 
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9 SWEDISH SUMMARY 
Bakgrund. För policybeslut avseende valet mellan alternativa behandlingsmetoder inom 
hälso- och sjukvården är det viktigt att identifiera vilken som ger mest nytta för givna 
resurser. För sådana beslut krävs hälsoekonomiska utvärderingar. Den här avhandlingen 
analyserar kostnadseffektiviteten av avancerad postoperativ smärtbehandling och 
perioperativ optimering av cirkulation hos äldre med höftfraktur genom tillämpning av 
hälsoekonomiska modeller. 
1. De två vanligaste formerna av avancerad postoperativ smärtlindring efter större 
operationer är epidural och intravenös patientkontrollerad smärtlindring. Epidural 
smärtlindring har bättre effekt och används som standard. En nackdel med epidurala 
behandlingen är den höga andelen avbrutna behandlingar (10-15%). Eftersom cirka 40 000 
patienter behandlas varje år i Sverige blir frågan om kostnadseffektivitet betydelsefull. 
2. För postoperativ återhämtning är det viktigt med optimalt blodflöde under operation. Detta 
kan uppnås med hjälp av olika strategier för perioperativ vätskebehandling och optimering av 
cirkulation. En av dessa är s.k. målstyrd hemodynamisk optimering som öka blodflödet till 
definierade mål. Hos högriskpatienter främjar metoden den postoperativa återhämtningen, 
men nyttan hos äldre är inte klarlagd. I Sverige opereras årligen 20 000 patienter för 
höftfraktur. Risken för postoperativa komplikationer är hög. Kliniska studier behövs för att 
analysera den kliniska effekten och kostnadseffektiviteten av målstyrd hemodynamisk 
optimering. Sådana studier är komplexa och resurskrävande. En förhandsskattning av 
förväntade kostnader och nytta kan motivera initieringen och genomförandet av studier. 
Metoder 
1. Epidural smärtlindring jämförd med intravenös patientkontrollerad smärtlindring:  
Studie I: En kostnadseffektivitetsmodell konstruerades för att analysera data från en klinisk 
kvalitetsdatabas. 
Studie II: Postoperativa intensivvårdskostnader analyserades från patienter som ingick i en 
publicerad studie av postoperativ smärtbehandling efter matstrupsoperation för cancer. 
2. Målstyrd hemodynamisk optimering jämfördes med traditionell vätskebehandling:  
Studie III: En kostnadseffektivitetsmodell konstruerades och relevanta uppgifter från studier 
och nationella register användes. Eftersom det kliniska utfallet hos äldre inte är helt klarlagt 
försågs modellen med rimliga skattningar. 
Studie IV: Baserat på föregående kostnadseffektivitetsanalys startades en klinisk 
randomiserad studie med planerad inklusion av 460 äldre patienter med höftfraktur. Vid 
interimsanalysen på 100 patienter sågs en effekt men med statistisk osäkerhet. Det 
förväntade värdet av perfekt information analyserades baserat på den konstaterade 
osäkerheten. Med begreppet avses det samhälleliga värdet, uttryckt i pengar, av att minska 
den statistiska osäkerheten genom fortsatt datainsamling. 
Resultat  
1. Epidural smärtlindring är inte kostnadseffektiv och ingen besparing av postoperativa 
kostnader kan uppnås baserat på uppgifter i klinisk svensk rutin (artikel I-II). 
2. Hälsoekonomisk modellanalys gör troligt att målstyrd hemodynamisk optimering av äldre 
är kostnadseffektiv. Det förväntade värdet av perfekt information är högt (artikel III-IV). 
Slutsatser.  
1. Analyserna av epiduralbedövning utmanar den epidurala smärtlindringens ställning som 
gyllene standard i ett hälsoekonomisk perspektiv. 
2. Förhandsanalys av målstyrd hemodynamisk behandling hos äldre motiverar en klinisk 
studie. Analysen av det förväntade värdet av perfekt information i samband med en 
interimanalys indikerar ett högt samhälleliga värde av fortsätt datainsamling.  
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